Iridium(III) coordination compounds based on organophosphorus ancillary ligands showing cytotoxicity against breast cancer cells and Fe(III) luminescent sensing.

TYPE Review PUBLISHED 05 February 2024 DOI 10.3389/fbioe.2024.1354286 OPEN ACCESS EDITED BY Zehua Liu, University of Helsinki, Finland REVIEWED BY Cheng Hu, Sichuan University, China Jiulong Zhao, Naval Medical University, China Zonghao Tang, Southwest Medical University, China Enhancing diabetic wound healing: advances in electrospun scaffolds from pathogenesis to therapeutic applications Xuewen Jiang 1†, Yu-E Zeng 2†, Chaofei Li 3, Ke Wang 1* and Deng-Guang Yu 1* 1 *CORRESPONDENCE Ke Wang, wangk2017@usst.edu.cn Deng-Guang Yu, ydg017@usst.edu.cn School of Materials and Chemistry, University of Shanghai for Science and Technology, Shanghai, China, Department of Neurology, Ruijin Hospital Lu Wan Branch, Shanghai Jiao Tong University School of Medicine, Shanghai, China, 3Department of General Surgery, Ruijin Hospital Afﬁliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China 2 † These authors have contributed equally to this work RECEIVED 12 December 2023 ACCEPTED 17 January 2024 PUBLISHED 05 February 2024 CITATION Jiang X, Zeng Y-E, Li C, Wang K and Yu D-G (2024), Enhancing diabetic wound healing: advances in electrospun scaffolds from pathogenesis to therapeutic applications. Front. Bioeng. Biotechnol. 12:1354286. doi: 10.3389/fbioe.2024.1354286 COPYRIGHT © 2024 Jiang, Zeng, Li, Wang and Yu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. Diabetic wounds are a signiﬁcant subset of chronic wounds characterized by elevated levels of inﬂammatory cytokines, matrix metalloproteinases (MMPs), and reactive oxygen species (ROS). They are also associated with impaired angiogenesis, persistent infection, and a high likelihood of hospitalization, leading to a substantial economic burden for patients. In severe cases, amputation or even mortality may occur. Diabetic foot ulcers (DFUs) are a common complication of diabetes, with up to 25% of diabetic patients being at risk of developing foot ulcers over their lifetime, and more than 70% ultimately requiring amputation. Electrospun scaffolds exhibit a structural similarity to the extracellular matrix (ECM), promoting the adhesion, growth, and migration of ﬁbroblasts, thereby facilitating the formation of new skin tissue at the wound site. The composition and size of electrospun scaffolds can be easily adjusted, enabling controlled drug release through ﬁber structure modiﬁcations. The porous nature of these scaffolds facilitates gas exchange and the absorption of wound exudate. Furthermore, the ﬁber surface can be readily modiﬁed to impart speciﬁc functionalities, making electrospinning nanoﬁber scaffolds highly promising for the treatment of diabetic wounds. This article provides a concise overview of the healing process in normal wounds and the pathological mechanisms underlying diabetic wounds, including complications such as diabetic foot ulcers. It also explores the advantages of electrospinning nanoﬁber scaffolds in diabetic wound treatment. Additionally, it summarizes ﬁndings from various studies on the use of different types of nanoﬁber scaffolds for diabetic wounds and reviews methods of drug loading onto nanoﬁber scaffolds. These advancements broaden the horizon for effectively treating diabetic wounds. KEYWORDS nanoﬁber, electrospinning, wound dressing, diabetic foot ulcers, nanostructures 1 Introduction Diabetes mellitus (DM) is a metabolic disease characterized by chronic hyperglycemia resulting from various factors. It occurs due to defects in insulin secretion and/or action. The classic symptoms of DM, referred to as “three polys and one loss,” include polyuria, polydipsia, polyphagia, and weight loss, often accompanied by skin itching. Prolonged metabolic disorders in carbohydrate, fat, and protein metabolism can lead to a range of Frontiers in Bioengineering and Biotechnology 01 frontiersin.org Jiang et al. 10.3389/fbioe.2024.1354286 FIGURE 1 Epidemiological survey of diabetes in China and worldwide (Aschner et al., 2021). without vascular reconstruction (Peter-Riesch, 2016). Consequently, DFU is a leading cause of non-traumatic amputations and incurs substantial treatment costs, making it a signiﬁcant social issue. Why is DFU therapy expensive? To understand this, we need to examine why wound healing is challenging and what factors prolong the healing process. Peripheral neuropathy, deformities, and macrovascular disease are major contributors to the failure of DFU healing (Veves et al., 2001). Other signiﬁcant factors affecting DFU include low ﬁbroblast proliferation, receptor downregulation, and inadequate protein matrix in the dermis (Marston et al., 2003). In summary, the mechanisms involved are complex, but they provide ample scope for the treatment of DFU. The treatment approaches for DFU vary based on individual symptoms and disease stage. Regulating blood glucose levels and appropriate insulin therapy have shown high efﬁcacy in wound closure (Veves et al., 2001). Other methods, such as revascularization (Liu et al., 2019), hyperbaric oxygen therapy (Raspovic et al., 2022), and granulocyte colony-stimulating factor (Yellin et al., 2022), have also been used. However, in most cases, wound dressings create an optimal environment for open wounds, leading to better and faster wound closure (Futrega et al., 2014). However, traditional wound dressings, such as gauze, have limited functionality due to inherent material defects. They can only partially replace the functions of damaged skin and provide a microenvironment for wound healing. Normal wound healing progresses through different stages with distinct pathological characteristics. Therefore, an efﬁcient local administration method is needed to aid in the healing of diabetic wounds. In recent years, new drug delivery systems, including ﬁbrous membranes, foams, and hydrogels, have emerged. However, nanoﬁbers have shown superior results in promoting the formation of new skin tissues, vascular remodeling, and exudate absorption (Gao et al., 2022). The porous structure of nanoﬁbers facilitates the continuous delivery of drugs and allows for easy surface modiﬁcation to impart speciﬁc function (Gao et al., 2021). chronic complications, such as progressive lesions, dysfunction, and failure of vital organs like the eyes, kidneys, nerves, heart, and blood vessels (ElSayed et al., 2023). Severe metabolic disorders can occur during instances of disease severity or stress, contributing to the high global mortality rate associated with diabetes. Consequently, this disease places signiﬁcant ﬁnancial strain on healthcare systems worldwide. Type 1 diabetes (T1DM) and type 2 diabetes (T2DM) are the most prevalent forms, both exhibiting evident genetic heterogeneity. Additionally, there are other speciﬁc causes of diabetes, such as young-onset adult diabetes and diabetes caused by mitochondrial gene mutations (ElSayed et al., 2023). Despite variations in incidence and pathogenesis among these diabetes subtypes, the underlying pathological basis remains the body’s inability to properly handle and utilize glucose, resulting in elevated blood glucose levels (Tomic et al., 2022). Currently, an estimated 537 million people worldwide are affected by diabetes (Sun et al., 2022). Over the past 2 decades, the global prevalence of diabetes mellitus has signiﬁcantly increased, primarily driven by diverse social and economic factors. Projections indicate that by 2045, approximately 780 million people will have diabetes, representing an almost 50% increase within the next 20 years (Aschner et al., 2021) (Figure 1). Diabetic foot ulcer (DFU) is a common and serious complication of diabetes characterized by the development of lower extremity ulcers and gangrene due to macrovascular and microvascular lesions (McDermott et al., 2023). Advancement to the gangrene stage can result in amputation or even death. Peripheral neuropathy and peripheral vascular disease (PAD) are major contributing factors to the development of DFU (Monteiro-Soares et al., 2023). Neuropathy can lead to intrinsic foot muscle contracture, causing claw toe deformity and increased pressure on the metatarsal head, making this area more susceptible to ulcers. Flexion of the proximal interphalangeal joint increases the risk of ulceration on the dorsal side of the joint and the metatarsal side of the toe. Vascular lesions hinder tissue healing, and even minor arterial insufﬁciency injuries have little chance of healing Frontiers in Bioengineering and Biotechnology 02 frontiersin.org Jiang et al. 10.3389/fbioe.2024.1354286 FIGURE 2 (A) Wound healing and its major cellular components. The repair of wounds begins with the coagulation phase, where platelet embolization prevents blood loss and the formation of the initial ﬁbrin matrix. This is followed by the inﬂammation stage, which serves to remove debris and prevent infection. The inﬂux of neutrophils is promoted by the release of histamine by mast cells. Monocytes then migrate to the site of injury and differentiate into tissue macrophages, which help clear residual cell debris and neutrophils. During the proliferation phase, keratinocytes migrate to close the wound space, angiogenesis occurs to reconstruct blood vessels, and ﬁbroblasts replace the initial ﬁbrin clot with granulation tissue. Macrophages and regulatory T cells play critical roles in this stage of healing. Finally, in the remodeling stage, ﬁbroblasts further remodel the deposited matrix, while vascular degeneration and myoﬁbroblasts contribute to overall wound contraction. (B) Factors inﬂuencing wound healing in diabetes. Diabetic wound keratinocytes display abnormal activation, leading to impaired hyperproliferation and migration. Additionally, a signiﬁcant number of chronic inﬂammatory cells, such as macrophages and ﬁbroblasts, undergo senescence and exhibit a senescence-associated secretory phenotype (SASP). This perpetuates senescence, triggers the release of reactive oxygen species (ROS), and exacerbates inﬂammation. as the different structures of nanoﬁber scaffolds prepared through electrospinning. We then summarize the application of various types of electrospinning scaffolds and electrospinning scaffolds loaded with different drugs in promoting diabetic wound healing. Electrospinning technology enables precise adjustment of the composition and size of ﬁbers, making it a versatile tool in various biomedical ﬁelds such as medical implants (Singh et al., 2015), wound dressings (Felgueiras and Amorim, 2017), bone tissue engineering scaffolds (Udomluck et al., 2020), antibacterial agents (Mohammadi et al., 2019), drug delivery vehicles (Chakraborty et al., 2009), bionic actuators (Ke et al., 2014), dental materials (Zhao et al., 2022), and enzyme ﬁxation scaffolds (Stojanov and Berlec, 2020). The unique microstructure and appropriate mechanical properties of electrospun scaffolds resemble the nano-network structure of the natural extracellular matrix. This network structure facilitates absorption of wound tissue exudate and promotes gas exchange, enhancing skin tissue regeneration. Additionally, electrospun scaffolds support cell implantation, attachment, nutrient inﬁltration, and metabolic waste discharge, creating an optimal microenvironment for cell growth, proliferation, adhesion, migration, and differentiation (Kim et al., 2022; Dong et al., 2023; Zhao et al., 2023). Additionally, electrospun scaffolds offer the capability to load bioactive factors or drugs, such as antibiotics, anti-inﬂammatory agents, hypoglycemic drugs, inorganic nanoparticles, bioactive factors, and speciﬁc active cells. Moreover, the ﬁber structure can be adjusted to achieve precise control over drug release (Qian et al., 2023; Li et al., 2024; Yu and Zhou, 2024). Therefore, electrospun scaffolds hold great promise in the treatment of diabetic foot ulcers (Wang Y et al., 2022). In this paper, we provide a brief overview of the pathological mechanisms involved in normal and diabetic wound healing, as well Frontiers in Bioengineering and Biotechnology 2 Pathology and treatment of diabetic foot ulcers 2.1 Pathology of normal wound healing Wounds can be classiﬁed into two types based on their duration: acute wounds and chronic wounds. Acute wounds, such as surgical wounds, traumatic wounds, and burns, heal rapidly. Chronic wounds, on the other hand, deviate from the normal healing process and persist for more than 3 months. Examples include pressure ulcers, leg ulcers, and diabetic foot ulcers, which require a longer time to heal. General wound healing involves a series of interconnected and complex processes, involving immune cells, formation cells, as well as the cell factors, chemotactic factors, and growth factors they secrete, which coordinate all stages of healing. Traditionally, wound healing is divided into four consecutive stages: hemostasis following skin injury, an inﬂammatory response lasting several days, tissue regeneration lasting several days to 1 month, and tissue remodeling, as shown in Figure 2A. However, chronic wounds often stall before reaching the late healing stage (Liang et al., 2022). 03 frontiersin.org Jiang et al. 10.3389/fbioe.2024.1354286 The ﬁrst stage of normal wound healing is hemostasis, during which the body rapidly contracts blood vessels through a nerve reﬂex mechanism to prevent excessive blood loss caused by vascular damage (Sinegre et al., 2019). Blood platelets play a vital role in hemostasis and clotting. They immediately aggregate upon receiving signals from the extracellular matrix (ECM) (Maouia et al., 2020). The ECM then secretes proteins, such as ﬁbronectin and collagen, which attach to platelet receptors and form blood clots (Rojano et al., 2019). Blood clots are specialized structures composed of platelets embedded in various proteins, crucial for preventing bleeding (Yang et al., 2019; Zeng et al., 2020). In the subsequent 1–3 days, the wound enters the inﬂammatory response phase, during which neutrophils and anti-inﬂammatory macrophages gradually differentiate at the site of injury (Behm et al., 2012; Decker et al., 2016). These cells are capable of engulﬁng bacteria that cause infection and removing damaged cellular debris. During the tissue regeneration phase of wound healing, keratinocytes, ﬁbroblasts, macrophages, and endothelial cells differentiate to re-epithelialize cells, reconstruct vascular tissues, and promote ﬁber proliferation (Lau et al., 2009; Pan et al., 2021). This stage is characterized by the presence of immune cell subsets that facilitate healing, including M2 antiinﬂammatory macrophages and regulatory T cells (Tregs). The tissue remodeling stage typically lasts for 1 month but can extend for several months or even years. It primarily involves ﬁbroblasts, which utilize ﬁbrin protein clots to form scar tissue, accelerate neovascularization, and reshape collagen composition (Hinz, 2016). The entire process of normal wound healing begins with platelet aggregation, which forms blood clots at the wound site and secretes bioactive factors to promote immune cell differentiation and maintain blood vessel permeability. Neutrophils and inﬂammatory macrophages remove bacterial infections, debris, and dead cells through phagocytosis. Subsequently, the proinﬂammatory immune response transitions into a healingpromoting immune response, reducing inﬂammation and initiating the process of skin tissue remodeling. and the wound remains in a chronic state of inﬂammation (Peng et al., 2021). During general wound healing, ﬁbroblasts, keratinocytes, and immune cells secrete MMPs under the inﬂuence of local mediators. These mediators, such as transforming growth factor-beta (TGF-β), vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), and interleukins, are essential for tissue epithelialization and regeneration. However, in the high glucose environment of diabetes, the activation of the extracellular regulated protein kinases/activating protein-1 (ERK/AP1) signaling pathway can lead to excessive production of MMPs, resulting in rapid degradation of the extracellular matrix (ECM) (Roep et al., 2019). This affects the adhesion of ﬁbroblasts to the ECM, hindering the regeneration of skin tissue. Activated neutrophils can produce large quantities of matrix metalloproteinase 9 (MMP-9), further impeding the repair of diabetic ulcers (Nguyen et al., 2018). Under normal circumstances, macrophages transition from the M1 type that promotes inﬂammation to the M2 type that promotes wound repair under the inﬂuence of signaling factors, thus reducing inﬂammation. However, in diabetic wounds, macrophages fail to differentiate into the M2 type and instead produce pigment epithelium-derived factor (PEDF), which inhibits neovascularization. Additionally, neutrophils and M1 macrophages persist in the wound, sustaining inﬂammation and hindering the regeneration of skin tissue. Moreover, the high blood glucose environment in diabetic wounds promotes bacterial proliferation, leading to recurrent infections (Schreml et al., 2010). 2.3 Pathogenesis of diabetic foot ulcers Over time, diabetes can lead to microvascular and macrovascular complications, causing signiﬁcant pain and suffering for patients. These complications are important factors in the development and progression of diabetic foot ulcers (DFUs). Additionally, immune damage, reactive oxygen species (ROS) production, and bacterial infections also contribute to the development of DFUs (Madhukiran et al., 2021). Diabetic neuropathy (DN) is another complication that can lead to the development of DFUs in diabetic patients (Feldman et al., 2019). The hyperglycemic environment in diabetes often disrupts the arrangement of Schwann cells and axons, leading to impaired peripheral nerve function in DN patients. This disruption also affects the microcirculation of the limbs, resulting in additional nerve damage and loss of foot pain perception (Gumy et al., 2008). The absence of pain sensation makes patients unaware of wounds or ulcers, leading to their enlargement and subsequent infection (Feldman et al., 2019). DN can damage axons, disrupt foot circulation, cause peripheral arterial disease (PAD), and further worsen the condition (Megallaa et al., 2019, p. 2). During the inﬂammatory response stage of DFUs, the phagocytic function of macrophages is impaired, resulting in an abundance of M1 macrophages and a prolonged inﬂammatory state in diabetic wounds. This leads to continuous release of matrix metalloproteinases (MMPs) and rapid degradation of collagen and the extracellular matrix (ECM) (Zhao et al., 2017). Furthermore, the polarization of M1 macrophages slows down the rate of re-epithelialization (Huang et al., 2019). DFUs produce excessive reactive oxygen species (ROS), leading to increased oxidative stress (Singh et al., 2008). These excess ROS react with nitric oxide (NO) to generate peroxynitrite anion (NO2−), which interferes with wound healing (Sadati et al., 2018). 2.2 Pathology of wound healing in diabetes Diabetic wounds, including chronic wounds, deep wounds, infected wounds, and ulcer wounds, are characterized by persistent inﬂammation, recurrent infections, impaired angiogenesis, impaired tissue epithelialization, and excessive levels of matrix metalloproteinases (MMPs) and reactive oxygen species (ROS) (Holl et al., 2021). Diabetic wounds are one of the three major types of chronic wounds, with the other two being vascular ulcers and pressure ulcers. The hemostatic and inﬂammatory stages of chronic wound healing are similar to the normal wound healing process. However, unlike other chronic wounds, diabetic neuroischemic lesions and peripheral vascular lesions can signiﬁcantly impact wound healing. Additionally, there is often a persistent external wound infection, which hinders the transition from the inﬂammatory response stage to the tissue regeneration stage, thus slowing down the overall healing process (da Silva et al., 2019). Diabetic complications are commonly accompanied by vascular lesions, leading to nutritional deﬁciencies in wound healing. The hypoxic environment of the wound further complicates angiogenesis, Frontiers in Bioengineering and Biotechnology 04 frontiersin.org Jiang et al. 10.3389/fbioe.2024.1354286 the use of moist dressings to facilitate wound healing and restore blood supply (Tottoli et al., 2020). However, when these traditional treatments prove inadequate, new therapeutic approaches are sought. In recent years, our understanding of diabetic wounds has expanded, paving the way for the development of novel multi-functional wound scaffolds (Al-Dhahebi et al., 2022; Yu and Zhao, 2022; Si et al., 2023). Among these approaches, electrospinning technology is noteworthy. It is a well-established process for fabricating nanoﬁbers (Wang H et al., 2023), with a history spanning several centuries. By carefully adjusting the process parameters of the electrospinning equipment (such as receiving distance, voltage, and ﬂow rate), environmental variables (including humidity and temperature), and polymer solution variables (such as viscosity, solution electrical conductivity, capillary force, molecular weight, and polymer type), electrospun nanoﬁbers with desirable physical properties and excellent structures can be obtained. Electrospinning equipment typically consists of four components: a high voltage power supply, an injector, a spinning nozzle, and a receiving screen (as illustrated in Figure 3). The underlying principle involves applying an electrostatic ﬁeld of tens of thousands of volts between the injection device and the receiving device, resulting in the formation of a jet from the tapered end of the spinning solution. This jet is then stretched within the electric ﬁeld and ultimately forms a nonwoven nanoﬁber structure on the receiving device (Kang et al., 2020). Moreover, in a hyperglycemic environment, the increased ROS levels promote the formation of advanced glycation end products (AGEs) (Kim and Kwon, 2014). Additionally, hyperglycemia increases glycosylation and enhances intercellular interactions in keratinocytes, resulting in delayed wound closure (Huang et al., 2017) (shown in Figure 2B). 2.4 Therapeutics for diabetic foot ulcers Early control in the development of DFU is crucial for successful treatment, similar to many critical illnesses. Traditional wound healing strategies can be categorized into four aspects: unloading, blood glucose control, debridement, and infection management. DFUs typically occur in high-pressure areas of the foot, underscoring the importance of pressure redistribution (unloading) during DFU therapy. Various methods can be employed to reduce stress, including the use of canes, wheelchairs, surgical interventions, surgical shoes, bandages, and more. Total Contact Castings (TTC) made from specialized materials are widely regarded as the most effective method for unloading during the DFU healing process. Compared to dressings, TTCs have been shown to signiﬁcantly shorten the healing time of DFUs (Sahu et al., 2018). However, TTCs also have notable disadvantages. They require the expertise of well-trained staff and patient compliance can be poor. In many cases, they cannot be successfully removed, and improper use can even worsen the condition. Long-term hyperglycemia in diabetic patients can have a detrimental impact on DFU healing, making glycemic control necessary. Glycemic control is typically achieved through medication and a controlled diet to maintain normal blood glucose levels. Debridement is an essential component of standard DFU care, as it promotes wound healing by removing necrotic tissue and reducing bacterial bioﬁlm and excess matrix proteins. Various types of debridement exist, with surgical debridement being the most commonly used. However, one must be cautious with debridement as it requires time and multiple procedures to yield positive therapeutic effects. A slight oversight can lead to the rapid and severe progression of diabetic foot conditions. In patients with DFUs who progress to the point of requiring amputation, the ulcerated area often presents with severe infection (Huang et al., 2022b). This is primarily due to the prolonged exposure of the wound in diabetic patients. Infections are typically managed with orally administered antibiotics, which pose signiﬁcant limitations to treatment (Zhang et al., 2023). High antibiotic concentrations can have serious side effects on the human body. Therefore, it is imperative to explore new strategies for DFU treatment and management (Hu et al., 2021). 3.2 Advantages of electrospun nanoﬁber scaffolds in diabetic wound healing One of the main advantages of electrospinning is the ability to create highly porous ﬁber structures that mimic the extracellular matrix (ECM) and that aid in wound healing (Sell et al., 2010). this makes it an excellent choice for the fabrication of DFU therapeutic scaffolds (as shown in Table 1). By optimizing the processing and environmental parameters of electrospinning, the porosity and pore size of the scaffolds can be tuned to promote diffusion. This porous structure facilitates gas exchange at the wound site and can also serve as a platform for drug loading, allowing for controlled drug release through structural adjustments (Samadian et al., 2020). The constructed scaffold exhibits a high speciﬁc surface area and volume ratio, resulting in increased drug loading capacity and consistent drug release. Moreover, its porous nature promotes wound desiccation, creating an ideal healing environment (Junker et al., 2013). Electrospinning can produce nano-scale scaffold ﬁbers, increasing the surface area available for cell adhesion and facilitating wound healing (Glover et al., 2021). To effectively treat DFU, it is important to focus on vascularization, collagen accumulation, and normal physiological function. This will help control the deterioration process and promote wound healing (Lv et al., 2017). Although DFU patients often struggle to heal on their own, biomolecules and active drugs, such as antibiotics, can provide much-needed assistance. Electrospun nanoﬁber scaffolds are an excellent platform for carrying active drugs due to their controlled-release capabilities. Additionally, nanoﬁber scaffolds can positively inﬂuence exudate uptake and exchange of oxygen, water, and nutrients, which are vital activities in wound healing (Kim et al., 2012). 3 Nanoﬁber scaffolds with various structures prepared by electrospinning 3.1 Introduction to electrospinning technology The treatment of diabetic wounds and DFUs involves debridement, improved glucose regulation, infection control, and Frontiers in Bioengineering and Biotechnology 05 frontiersin.org Jiang et al. 10.3389/fbioe.2024.1354286 FIGURE 3 Schematic diagram of electrospinning equipment. TABLE 1 Comparison of electrospun nanoﬁber scaffolds and extracellular matrix (ECM) (Sell et al., 2010). ECM Electrospun scaffolds Components ECM composition consists of a dynamic three-dimensional arrangement of polysaccharides and natural polymers (collagen, elastin, ﬁbrinogen, etc.) Electrospun scaffolds are mostly prepared from synthetic and natural polymers Structures The ECM structure consists mainly of ﬁbres with diameters between 50 and 500 nm Most of the nanoﬁbres prepared by the electrostatic spinning technique have diameters ranging from 10 μm to 500 nm Role in wound healing i. During development, cell-ECM interaction is responsible for pattern formation, morphogenesis, and phenotype acquisition and maintenance i. Have appropriate porosities to allow for cellular migration and penetration ii. During clot formation, wound healing, inﬂammation, formation of granulation tissue, and remodeling are all mediated by cell-ECM interaction ii. Have sufﬁcient surface area and the proper surface chemistry to promote cell adhesion, growth, migration, and differentiation iii. Cell adhesion, migration, growth, differentiation and apoptosis are all based on a structural framework of tissue composed of ECM. iii. A rate of degradation that closely matches the rate of native tissue regeneration to promote proper tissue ingrowth potential of both ZnO-loaded and ZnO-free scaffolds were evaluated, demonstrating excellent antibacterial and antioxidant properties. These scaffolds, which exhibited antibacterial properties against both Gram-positive and Gramnegative bacteria, were further tested for wound healing in rats, both with and without cells. The results showed successful wound healing and complete epithelial regeneration (RanjbarMohammadi et al., 2016). Coaxial electrospinning technology was employed to fabricate a core-shell scaffold composed of chitosan and polylactic acid, which improved its mechanical properties and enhanced cell adhesion and proliferation. This scaffold has found applications in tissue engineering (Surucu and Different types of electrospun scaffold structures require speciﬁc preparation methods, including single-ﬂuid and twoﬂuid electrospinning, as well as the emerging multiﬂuid electrospinning (as shown in Figure 4). Scaffolds prepared using these methods possess unique advantages for wound healing applications. For instance, Ren et al. (Han et al., 2019) investigated the role of oriented scaffolds prepared by single-ﬂuid electrospinning in wound healing and observed a signiﬁcant enhancement in cell adhesion. Ahmed et al. (Ahmed et al., 2018) developed a zinc oxide (ZnO)-loaded chitosan/polyvinyl alcohol core-shell nanoﬁber scaffold using electrospinning technology. The antibacterial efﬁcacy and antioxidant Frontiers in Bioengineering and Biotechnology 06 frontiersin.org Jiang et al. 10.3389/fbioe.2024.1354286 FIGURE 4 Schematic diagram illustrating quadriaxial electrospinning, with the inset in the upper right corner displaying a photograph of the concentric spinneret (Zhang et al., 2021). and ease of operation. However, blend electrospinning also has its drawbacks, as it requires the polymer to be spinnable (Wu et al., 2020). By combining two different polymers through blend electrospinning, uniaxial nanoﬁber scaffolds can be prepared, inheriting the advantageous properties of both polymers, such as good mechanical properties and biocompatibility. However, it is possible for these scaffolds to exhibit deﬁciencies in certain properties, which can be improved by incorporating additional polymers or utilizing physical techniques such as cross-linking or lyophilization. For instance, Lv et al. (2022) successfully fabricated a series of blend electrospun nanoﬁbers by combining chitosan (CS) and polyvinyl alcohol (PVA) with the addition of ursolic acid (UA). The resulting CS-PVA-UA nanoﬁber scaffolds exhibited a morphology resembling collagen ﬁbers in the natural skin extracellular matrix, along with excellent surface hydrophilicity, wettability, and hemostatic properties. The addition of UA to CSPVA nanoﬁbers also demonstrated good biocompatibility and drug release properties. In vivo experiments conducted on diabetic mice showed that the nanoﬁber scaffold effectively inhibited inﬂammation and oxidative stress, promoted angiogenesis, collagen deposition, epithelial formation, and hair follicle regeneration, ultimately achieving wound healing. Gholipour-Kanani et al. (2016) prepared chitosan-polyvinyl alcohol nanoﬁber scaffolds, and subsequently incorporated polycaprolactone (PCL) to enhance mechanical and biological properties. These scaffolds were tested in both a diabetic rat back skin wound model and a diabetic foot ulcer wound model. The results showed signiﬁcant reduction in wound area and increased new granulation tissue formation in rats treated with the nanoﬁber scaffolds. Complete wound closure was achieved within 20 days of resection. The addition of PCL improved the mechanical and biological properties of the scaffolds. Sasmazel, 2016). Furthermore, electrospun scaffolds can be combined with 3D printing techniques to replicate the ECM matrix structure, thereby promoting wound healing in diabetes (Mellor et al., 2017; Zhang et al., 2021). 4 Application of electrospun scaffolds for diabetic foot ulcers The nanoﬁber scaffolds fabricated through electrospinning technology have demonstrated exceptional properties for wound healing. Their tissue structure closely resembles the extracellular matrix (ECM) found in human skin, thereby promoting the regeneration of new skin. Additionally, these scaffolds serve as versatile platforms for drug loading and delivery, enabling the targeted delivery of wound-healing agents to expedite the healing process. Consequently, electrospun scaffolds are considered ideal materials for treating chronic wounds (Jeckson et al., 2021). Given that diabetic wounds represent a signiﬁcant subset of chronic wounds, the application of electrospun scaffold materials holds immense potential in the ﬁeld of diabetic wound healing (Zhou et al., 2023b) (as shown in Table 2). 4.1 Uniaxial nanoﬁber scaffold for diabetic wounds Uniaxial nanoﬁber scaffolds are typically prepared through blend electrospinning, where the drug and polymer solutions are mixed and electrospun through a single nozzle. Traditional singleaxis electrospinning has garnered signiﬁcant attention from researchers due to its simplicity, cost-effectiveness, high yield, Frontiers in Bioengineering and Biotechnology 07 frontiersin.org Jiang et al. 10.3389/fbioe.2024.1354286 TABLE 2 Advantages and disadvantages of different electrospinning structures. (Wang Y et al., 2023; Chen et al., 2024; Duan et al., 2024). Technique Polymer Active ingredients Highlights Ref. Blend CS/PVA Ursolic acid CS-PVA-UA nanoﬁber scaffolds are morphologically similar to the natural skin extracellular matrix and have excellent surface hydrophilicity, wettability, and hemostatic properties Lv et al. (2022) Polyvinyl alcohol/PVA Chitosan The addition of PCL improved the mechanical and biological properties of the scaffolds Gholipour-Kanani et al. (2016) GZS Cu Graphene oxide enhanced mechanical stability and swellability of the scaffold, and copper ions were incorporated as a bactericide and angiogenesis promoter El-Lakany et al. (2020) PVA EPP1 PVA/EPP1 ﬁber scaffolds exhibited excellent water absorption and antiinﬂammatory activity Guo et al. (2022) TE/collagen — Makes the new skin on the wound closer to the natural uninjured skin Kellar et al. (2020) PVA/calcium alginate Idebenone the scaffold promoted new skin formation while reducing oxidative stress and inﬂammation Jintao (2022) PVA/PCL DOX Achieved continuous release of DOX in response to pH by utilizing the sensitivity of PVA to pH Yan et al. (2020) PLGA Insulin The scaffold releases insulin for up to 4 weeks Lee et al. (2020a) PLA/PVA CTGF PLA/PVA scaffolds have high biocompatibility and biosafety.the scaffolds can help with vascular remodeling Augustine et al. (2019) PLGA PDGF, vancomycin The scaffold could stably release PDGF and antibiotics for up to 3 weeks, enhanced neovascularization around the wound area Lee et al. (2020b) TE/collagen — Makes the new skin on the wound closer to the natural uninjured skin Kellar et al. (2020) Janus PVP/EC TAM During the initial stage of drug release, TAM-PVP demonstrated a more rapid burst release and a slower sustained release in the subsequent phase, whereas TAM-EC exhibited the opposite pattern Zheng et al. (2021) Three-layered PCL/gelatin/ PLGA BSA/RHB A novel and robust triﬂuid electrospun ﬁbrous scaffold was developed with dual drug delivery capabilities Nagiah et al. (2020) Eudragit S100 Aspirin The nanoﬁbers exhibited a stable and sustained release of the drug, thereby avoiding the risk of excessive administration Ding et al. (2020) CA ACY The drug release proﬁle exhibited a consistent and controlled release of ACY throughout the testing period Wang et al. (2020) PCL/collagen lignocaine extract These ﬁndings indicate that the herbal extracts did not affect the physical properties of the scaffolds, but signiﬁcantly augmented their bioactivity, making them valuable for the treatment of diabetic ulcers Derakhshan et al. (2022) Coaxial wound healing, reduced inﬂammatory response, and closer resemblance to unwounded skin compared to the control group. Jintao (2022) prepared PVA/calcium alginate scaffolds through blend electrospinning and loaded idebenone at different concentrations for diabetic wound healing. The scaffold loaded with 1% idebenone demonstrated the best performance. In vivo evaluation using a rat diabetic wound model showed that the scaffold group achieved the fastest wound closure rate. Histological immunostaining experiments revealed that the scaffold promoted new skin formation while reducing oxidative stress and inﬂammation. El-Lakany et al. (2020) introduced a copper-grafted graphene oxide cross-linked zein electrospun scaffold (Cu-GZS) for promoting healing of skin excision wounds in diabetic male rats. Graphene oxide enhanced mechanical stability and swellability of the scaffold, and copper ions were incorporated as a bactericide and angiogenesis promoter. The optimized Cu-GZS exhibited a constant copper release rate and accelerated wound closure, as evidenced by reduced leukocyte inﬁltration, intact epithelium with normal keratinization, and faster wound size reduction. Guo et al. (2022) developed a nanoﬁbrous scaffold composed of marshmallow polysaccharide (EPP1) and polyvinyl alcohol (PVA), which exhibited excellent water absorption and anti-inﬂammatory activity. In vitro and in vivo experiments demonstrated that PVA/ EPP1 ﬁber scaffolds accelerated wound repair in diabetic mice. Kellar et al. (2020) investigated the synthesis of electrospun biomimetic scaffolds containing Tropoelastin (TE) and collagen. In vivo experiments using a diabetic mouse model revealed that the scaffold group exhibited increased neoplastic skin tissue, faster Frontiers in Bioengineering and Biotechnology 4.2 Multiﬂuid electrospun nanoﬁber scaffold for diabetic wounds Due to the limitations of uniaxial nanoﬁber scaffolds, it is difﬁcult to prepare more complex nanostructures. As a result, a multi-ﬂuid electrospinning technique has been developed, in which 08 frontiersin.org Jiang et al. 10.3389/fbioe.2024.1354286 TABLE 3 Summary of different electrospun nanoﬁbre scaffolds in the treatment of diabetic foot. Double-ﬂuid electrospinning Multiﬂuid electrospinning Coaxial electrospinning Side-by-side electrospinning Three-ﬂuid electrospinning i. The drug is loaded into the core layer, and the drug is effectively protected from the external environment through the shell layer i. Both sides of the polymer material and the drug are in direct contact with the outside world Triaxial electrospinning is an improved process based on coaxial and juxtaposition electrospinning, which share their common advantages and are capable of constructing more complex drug controlled release systems ii. By adjusting the composition and thickness of the ﬁbres of the core-shell layer, the function of controlling the slow release of the drug is achieved iii. Encapsulate different drug molecules in the coresheath layer separately to prepare a multistage multieffect drug release system ii. It is able to constitute a dual-drug biphasic release drug release system, which helps the drug to be released rapidly iv. The non-spinable polymer can be used as the core layer and the spinnable polymer as the shell layer, so that the shell layer can drive the core layer to electrospin, and the non-spinable polymer nanoﬁbres can be prepared i. At best, nanoﬁbres capable of controlled release of two drugs have been prepared, which does not fully satisfy more complex and difﬁcult therapeutic requirements i. It is difﬁcult to achieve the slow drug release effect of coaxial electrospinning ii. The preparation process is more complex and the parameters are more difﬁcult to regulate compared to single-ﬂuid electrospinning ii. Similarly, juxtaposition electrospinning does not meet more complex and difﬁcult therapeutic needs. It is also more complicated in the preparation process with the control group, type I collagen decreased and transforming growth factor-β increased in the scaffold group. This demonstrates the beneﬁt of the core-shell scaffold, which allows for the delayed release of medication and aids in wound healing. Augustine et al. (2019) developed an electrospun dual porous polylactic acid/polyvinyl alcohol (PLA/PVA) nanoﬁber scaffold loaded with connective tissue growth factor (CTGF). CTGF was loaded into the polyvinyl alcohol sheath. The scanning electron microscope (SEM) results showed high porosity in the scaffold with secondary pores on the surface of many single ﬁbers. Cell experiments demonstrated that PLA/PVA scaffolds have high biocompatibility and biosafety. The drug release curve also showed stable release of CTGF. Chicken chorioallantoic membrane (CAM) experiments further demonstrated that the scaffolds can help with vascular remodeling. Lee et al. (2020b) developed a PLGA nanoﬁber core-shell scaffold loaded with antibiotics and platelet-derived growth factor (PDGF). In this scaffold, PDGF acts as the outermost shell, while the core layer consists of a mixture of PLGA and vancomycin. Drug release experiments showed that the scaffold could stably release PDGF and antibiotics for up to 3 weeks. In vivo experiments showed that the scaffold enhanced neovascularization around the wound area. Gupta and Wilkes published the ﬁrst study on the fabrication of Janus nanoﬁbers by side-by-side electrospinning in 2003 (Gupta and Wilkes, 2003). Side-by-side electrostatic spinning involves combining two spinnerets side-by-side to prepare Janus ﬁbers made of two materials that can both come into direct contact with the environment (Li et al., 2019; Lv et al., 2023a; Lv et al., 2023b). Zheng et al. (2021) used a side-by-side electrospinning procedure to create two Janus nanoﬁber scaffolds. The ﬁrst scaffold combined tamoxifen citrate (TAM) as the medicine and ethylcellulose (EC) as the polymer carrier matrix. The second scaffold, TAM-PVP, used TAM as the medication and polyvinylpyrrolidone (PVP) K60 as the polymer carrier matrix. Due to differences in PVP and EC solubilities, drug release tests demonstrated that biphasic drug release was feasible two or more solutions are pushed into a spinneret using various syringes for electrospinning. The main types of multi-ﬂuid electrostatic spinning processes are coaxial electrostatic spinning, side-by-side electrostatic spinning, and triaxial (three-layer coaxial, three-layer side-by-side) electrostatic spinning. Among the various electrospun nanoﬁbers, the core-shell nanoﬁber is the most widely used (Rathore and Schiffman, 2021). Compared with other nanoﬁbers (as shown in Table 3), the core-shell nanoﬁber scaffold can delay drug release and reduce its severity (Wang Y et al., 2023; Chen et al., 2024; Duan et al., 2024). To prepare nanoﬁber scaffolds with a core-sheath structure, two spinnerets of different apertures are used to nest into a concentric circle-like spinneret. The drug is loaded into the core layer, and the shell layer can slow down the release of the drug. Additionally, two different drugs can be loaded in this core-shell structured nanoﬁber, and the drugs can be released sequentially. The advantages of the coreshell type nanoﬁber structure are that it can achieve different sustained-release or quick-release effects based on the adopted macromolecules, and it can conveniently meet the transportation requirements of different drug (Han and Steckl, 2019). Therefore, it is considered to be one of the important breakthroughs in the drug delivery system (Pant et al., 2019; Yu and Huang, 2023). Yan et al. (2020) prepared a PVA/PCL core-shell nanoﬁber scaffold loaded with doxorubicin (DOX) using electrospinning technology and achieved continuous release of DOX in response to pH by utilizing the sensitivity of PVA to pH. Lee et al. (2020a) developed insulin-loaded poly-D-L-lactic-coglycolic acid (PLGA) core-shell nanoﬁber scaffolds that can stably release insulin to reduce blood sugar and aid in diabetic wound healing. They placed PLGA and insulin solutions into two syringes and electrospun them through two different injection pumps. The prepared scaffold releases insulin for up to 4 weeks. Additionally, the hydrophilicity of the core-shell scaffold is better than that of the mixed nanoﬁber scaffold. Gene expression detection showed that compared Frontiers in Bioengineering and Biotechnology The preparation process is very difﬁcult and requires a level by level modulation of parameters, with all the polymers and drugs affecting the preparation 09 frontiersin.org Jiang et al. 10.3389/fbioe.2024.1354286 for the two groups of ﬁbers. However, the drug release characteristics of the two ﬁber groups differed dramatically. During the initial stage of drug release, TAM-PVP demonstrated a more rapid burst release and a slower sustained release in the subsequent phase, whereas TAM-EC exhibited the opposite pattern. This demonstrates the effectiveness of the Janusnanoﬁber scaffold in achieving different drug release proﬁles (Hussein et al., 2022). Multiﬂuid electrospinning, including the triﬂuid electrospinning method, is an advanced technique that enhances the electrostatic spinning process by incorporating multiple solutions. One notable application of this technique is the fabrication of core-shell nanoﬁbers, which holds great potential for the treatment of diabetic wounds (Zhou et al., 2023c). In triﬂuid electrospinning, three ﬂuids are simultaneously electrospun, resulting in nanoﬁbers with a gradient structure consisting of three layers. The medication is typically loaded in the innermost layer, ensuring controlled and uniform release of the drug (Huang et al., 2022a). As a result, the release rate remains constant, eliminating the possibility of abrupt or excessive drug release. In a study conducted by Nagiah et al. (2020), a novel and robust triﬂuid electrospun ﬁbrous scaffold was developed with dual drug delivery capabilities. The scaffold consisted of a core layer made of PCL, a middle layer composed of gelatin loaded with bovine serum albumin (BSA) as the therapeutic drug, and a shell layer made of PLGA loaded with rhodamine B (RHB). The resulting nanoﬁbers exhibited superior mechanical properties and drug release capabilities compared to both uniaxial and coaxial ﬁbers. Ding et al. (2020) employed a modiﬁed triaxial electrospinning technique to fabricate core-shell nanoﬁbers using Eudragit S100 (ES100) as the base material, which was loaded with aspirin. The in vitro drug release experiments demonstrated that these nanoﬁbers exhibited a stable and sustained release of the drug, thereby avoiding the risk of excessive administration. In a similar vein, Wang et al. (2020) developed a novel approach for the preparation of three-layer nanoreservoirs and the construction of three-level core-sheath nanoﬁbers. The drug components comprised cellulose acetate and acyclovir (ACY). The drug release proﬁle exhibited a consistent and controlled release of ACY throughout the testing period. Derakhshan et al. (2022) conducted a study on a three-layer electrospun scaffold composed of PCL, PCL/collagen, and collagen. The collagen layer was supplemented with lignocaine extract, known to enhance the healing of diabetic wounds by promoting vascularization. Scanning electron microscopy analysis conﬁrmed the favorable morphology of the nanoﬁbers. In order to evaluate the wound healing efﬁcacy of the fabricated scaffolds, streptozotocin-induced diabetic rats were employed as an animal model. The three-layer electrospun scaffolds containing lignocaine extracts exhibited the highest mean wound closure diameter among the tested groups, surpassing PCL, PCL/collagen, and pure collagen. These ﬁndings indicate that the herbal extracts did not affect the physical properties of the scaffolds, but signiﬁcantly augmented their bioactivity, making them valuable for the treatment of diabetic ulcers (in Figure 5). structure (Kong et al., 2014), micropatterned structure (Kakunuri et al., 2017) and spider-web-like structure (Kim et al., 2013). These unique ﬁber structures offer advantages such as excellent adsorption capacity and stable mechanical properties. Sun et al. (2018) observed a distinctive basketweave-like structure in collagen ﬁbrils of natural skin. Inspired by this, they fabricated biomimetic nanoﬁber scaffolds with crossed ﬁber organization via electrospinning. Cell growth experiments comparing the crossed nanoﬁber scaffolds with aligned and random nanoﬁber scaffolds were conducted. The results demonstrated that the crossed nanoﬁber scaffold exhibited superior biocompatibility, enhanced cell growth, and improved cell adhesion compared to the other two groups. Using a diabetic rat wound model, the wound healing effects of the three nanoﬁber scaffold groups were compared. All three scaffold groups displayed better wound healing than the control group, but the crossed nanoﬁber scaffold group exhibited the fastest wound closure speed and the most favorable healing state. Additionally, the crossed nanoﬁber scaffold group exhibited a higher density of newly formed blood vessels. Sanhueza et al. (2021) developed a dual-size nanoﬁber scaffold composed of two polymer materials: poly-3-hydroxybutyrate (PHB) and gelatin (Ge). Ge improved the biocompatibility of the scaffold, while PHB crosslinked with Ge, enhancing the mechanical properties and porosity of the scaffold. In cell biological experiments, the double-sized Ge-PHB ﬁber scaffold effectively promoted ﬁbroblast adhesion, re-epithelialization, and exhibited a slow degradation rate as expected. Furthermore, in vivo data demonstrated that the Ge-PHB scaffold resulted in a larger wound healing area, faster wound closure rate, increased formation of new skin tissue, and greater neovascularization content. Wang J et al. (2022) developed a three-dimensional biomimetic nanoﬁber scaffold using electrospinning technology and surface modiﬁcation. The scaffold was designed to collect early bioﬂuids and respond to endogenous electric ﬁelds (EF). It exhibited high hydrophilicity and was composed of a polymer matrix of polydopamine and reduced graphene oxide, providing exceptional mechanical properties. The scaffold’s structure functioned as an “electronic skin,” facilitating wound gas exchange, absorbing wound exudates to generate endogenous bioelectricity, and promoting diabetic wound healing. Jiang et al. (2019) fabricated spacer-oriented nanoﬁber scaffolds with silicon-doped amorphous calcium phosphate nanocoatings (SiACP) on the surface using electrospinning. The substrate materials of the electrospun scaffolds were poly (D, L-lactic acid) (PDLLA) and polycaprolactone (PCL). Scanning electron microscopy (SEM) analysis revealed a random orientation of the nanoﬁbers, with only a small portion exhibiting porosity. The Si-ACP particles were uniformly distributed on the ﬁber surface. Drug release experiments demonstrated stable release of silicon ions. In vitro cellular investigations conﬁrmed the biocompatibility of the scaffolds and their ability to promote cell development. In vivo studies utilizing a diabetic mouse wound model showed that compared to a control group using a commercially available dressing, the scaffold group exhibited enhanced wound healing and accelerated neovascularization. Zhang et al. (2020) utilized coaxial electrospinning to fabricate a specially designed nanoﬁber scaffold coated with bioglass 4.3 Specially structured nanoﬁber scaffold for diabetic wounds Specially structured nanoﬁbers exhibit various arrangements, including random orientation (Inai et al., 2005), oriented-ordered Frontiers in Bioengineering and Biotechnology 10 frontiersin.org Jiang et al. 10.3389/fbioe.2024.1354286 FIGURE 5 (A) A schematic diagram illustrating the development of a drug delivery wound dressing by incorporating methaqualone into the matrix of an electrospun chitosan/carboxymethyl cellulose (CMC)-based scaffold (Abdelbasset et al., 2022). (B) Schematic diagram depicting the construction of biodegradable core-shell nanoﬁbers for the continuous and localized delivery of BIBR-277 to the wall of a balloon-injured artery in the abdominal aorta of diabetic rabbits (Lee et al., 2022). (C) Microscopic sections of skin samples from wounds following an 18-day treatment period, stained with Hematoxylin and eosin (H&E) and Masson’s trichrome (MT). Black arrows indicate crusty scabs, white arrows indicate the epithelial layer, yellow arrow indicates hair follicle, and asterisks indicate Sebaceous gland (Derakhshan et al., 2022). cytokine genes involved in macrophage differentiation. In vivo experiments using a diabetic mouse wound model showed that compared to the control group, the scaffold group reduced ROS content at the wound site and promoted new skin formation, vascular remodeling, and extracellular matrix (ECM) formation. Jiang et al. (2020) developed a micro-patterned scaffold by electrospinning and polydopamine coating, loading spherical bioactive glass on the surface. The scaffold matrix material was poly (ε-caprolactone) (PCL). The spherical bioactive glass was uniformly dispersed on the nanoﬁber surface, enabling stable release of calcium and silicon ions. In vitro experiments demonstrated that the scaffold had the potential to promote proliferation and vascular differentiation of human umbilical vein endothelial cells. Further in vivo experiments showed that the polydopamine-coated patterned scaffold efﬁciently promoted the nanoparticles for improving the healing of diabetic wounds. The therapeutic mechanism of the scaffold involved the controlled release of silicon and calcium ions from the bioglass, which promoted the production of biological factors associated with vascular remodeling in the wound. Additionally, the scaffold’s unique patterned structure provided a larger surface area for ﬁbroblast growth and adhesion, facilitating wound closure. In vivo experiments demonstrated that the use of the scaffold increased the number of new blood vessels in the wound and signiﬁcantly improved the wound closure rate. Furthermore, they prepared an oriented poly (L-lactic acid) (PLLA) ﬁber scaffold loaded with asiatic acid (AA) through blend electrospinning (Ren et al., 2018). The resulting nanoﬁbers exhibited a porous structure, with AA molecules evenly distributed on the ﬁber surface. The scaffold exhibited excellent biocompatibility and could regulate Frontiers in Bioengineering and Biotechnology 11 frontiersin.org Jiang et al. 10.3389/fbioe.2024.1354286 (CS) and polyvinyl alcohol (PVA) as polymer matrices. The scaffold exhibited excellent mechanical properties and hydrophilicity, with stable release of ANE. In vitro cell experiments conﬁrmed that ANE enhanced the biocompatibility of the scaffold. In vivo experiments using a diabetic mouse wound model demonstrated that compared to the blank scaffold group, the ANE-loaded scaffold group reduced the ROS content at the wound site and promoted new skin formation and vascular remodeling. Lei et al. (2022) reported a cellulose acetate-based nanoﬁbrous scaffold loaded with trilazad mesylate at concentrations of 1%, 3%, and 5%, and investigated the effects of scaffolds with different drug concentrations on diabetic wound healing. The scaffold exhibited good mechanical properties and water absorption, with sustained release of the drug. In vitro cell experiments showed that the scaffold with a 3% drug concentration displayed the best biocompatibility. Compared to the control group, the scaffold group exhibited signiﬁcantly improved wound healing. The scaffold reduced the ROS content at the wound site and promoted the formation of new skin and vascular remodeling. Tan et al. (2022) fabricated cellulose acetate nanoﬁber scaffolds incorporating 3%, 5%, and 10% w/w concentrations of pramipexole using electrospinning. The electrospinning technique allowed for the creation of nanoscale diameter ﬁbers and maintained the appropriate pramipexole content. In vitro cytotoxicity experiments demonstrated enhanced cell viability for cellulose acetate scaffolds containing 3% w/w pramipexole. In vivo experiments using a rat model of diabetic wounds were performed with this scaffold. The results showed that cellulose acetate scaffolds containing 3% pramipexole exhibited faster wound closure rates, increased epithelial thickness, and enhanced collagen deposition compared to scaffolds without the drug and control groups. Gene expression analysis demonstrated that drugloaded scaffolds signiﬁcantly reduced oxidative stress and alleviated inﬂammation. Kamal et al. (2022) fabricated nanoﬁber scaffolds using poly (3hydroxybutyric acid-3-hydroxyvaleric acid) (PHBV) loaded with cefadroxil (CPL) via electrospinning for the treatment of DFU infections. SEM analysis of the scaffold revealed uniform ﬁber diameter and smoothness. The scaffold exhibited excellent mechanical properties. The drug release proﬁle exhibited an initial burst release followed by a sustained release, lasting up to 2 days. In vitro cell experiments demonstrated good biocompatibility and safety of the scaffold, as well as effective antibacterial properties against methicillin-resistant S. aureus (MRSA). Cam et al. (2021) proposed a novel therapeutic strategy involving the preparation of chitosan/gelatin/polycaprolactone nanoﬁber scaffolds using electrospinning technology. Hypoglycemic drugs, including pioglitazone, metformin, and glibenclamide, were loaded into the polymers to enable the combination of oral hypoglycemic medications. Unlike the conventional solution mixing method, the drugs were loaded into the scaffold under pressure rotation. In vivo experiments were conducted using a rat model of diabetic wounds to evaluate the efﬁcacy of the scaffold. The treatment signiﬁcantly accelerated the healing process of diabetic wounds in type 1 diabetic rats. Additionally, the treatment led to the formation of densely organized collagen ﬁbers in the dermis, improved regeneration of both the dermis and epidermis, and reduced inﬂammation and edema compared to the group treated with a single drug. healing of diabetic wounds by enhancing re-epithelialization and collagen deposition. Moreover, the deliberate release of silicon ions from the scaffold had the potential to enhance angiogenesis and suppress inﬂammation at the wound site, ultimately improving diabetic wound healing. Su et al. (2020) developed a novel nanoﬁber scaffold for eradicating bacterial bioﬁlms in diabetic wounds. The scaffold consisted of two components: an electrospun nanoﬁber scaffold and a soluble microneedle array. The scaffold effectively delivered self-designed antimicrobial peptides both inside and outside the bioﬁlm, resulting in the resistance against a wide range of pathogens. In vivo results demonstrated the complete elimination of methicillin-resistant Staphylococcus aureus (MRSA) and resistance against Pseudomonas aeruginosa by the scaffold. 4.4 Electrospinning scaffold as drug-loading platform for diabetic wounds Currently, conservative treatment options, including drug therapy, are commonly used for patients with diabetes mellitus. Electrospun scaffolds serve as excellent drug-loading platforms, enabling the loading of various conventional drugs for diabetes treatment, such as antibiotics, hypoglycemic drugs, anti-inﬂammatory drugs, and natural drugs. They can also accommodate bioactive factors, inorganic nanoparticles, specialized biological cells, and other substances that have limited applicability in conventional treatments. Furthermore, in cases where a single drug may not provide optimal wound healing outcomes, electrospun scaffolds can be loaded with multiple drugs, leading to a synergistic therapeutic effect. 4.4.1 Electrospun scaffolds loaded with antibiotics, anti-inﬂammatory or hypoglycemic drugs Abbaszadeh et al. (2022) fabricated a cellulose acetate-based nanoﬁber scaffold loaded with probucol using electrospinning to enhance diabetic wound healing. Different concentrations of probucol-loaded scaffolds were prepared and tested. In vitro experiments demonstrated that the scaffold loaded with 1% probucol exhibited superior biocompatibility and cell protective properties. The wound healing ability of the scaffolds was evaluated in a rat model of diabetic excisional wounds. Compared to the drugfree control group, the scaffold group loaded with 1% probucol showed the most signiﬁcant improvement in wound healing. Gene expression analysis further revealed that the probucol-loaded scaffolds signiﬁcantly reduced the expression of the glutathione peroxidase gene. Maashi et al. (2023) developed a collagen-based nanoﬁber scaffold loaded with Nicaraven using electrospinning technology. The effects of the nanoﬁber scaffolds loaded with drug concentrations of 2%, 4%, and 6% on diabetic wounds were investigated. In vitro assessments demonstrated that the scaffolds were non-toxic to ﬁbroblasts and could mitigate the detrimental effects of oxidative stress on cells. In vivo studies using a rat model of diabetic wounds showed a signiﬁcant increase in wound closure rate, epithelial thickness, and collagen deposition in the scaffold groups with drug concentrations of 4% and 6%. Zhang et al. (2022) successfully developed a multifunctional nanoﬁber scaffold loaded with anemoside B4 (ANE) using chitosan Frontiers in Bioengineering and Biotechnology 12 frontiersin.org Jiang et al. 10.3389/fbioe.2024.1354286 neovascularization. The main therapeutic mechanism of the scaffold is the controlled release of magnesium ions through magnesium oxide, which inﬂuences the expression of biological factors associated with vascular remodeling. Subcutaneous implantation experiments using a rat model demonstrated that this scaffold degrades faster and induces a lower immune response. Within a week of implantation, the PCL/gelatin/MgO scaffolds led to the formation of robust blood vessels. The scaffolds also expedited the healing of diabetic wounds by suppressing inﬂammatory reactions and promoting angiogenesis and granulation. Huang et al. (2022b) fabricated a nanoﬁbrillar scaffold of cellulose acetate (CA) through electrospinning. The scaffold was then impregnated with 1.5% w/w puloxamer and subsequently utilized as a drug delivery platform for 30,000 inoculated menstrual blood stem cells (MenSCs). Wound healing assays were conducted using a diabetic rat excisional wound model. The results showed that the wound healing rate was signiﬁcantly improved in the CA/Puloxamer/MenSCs scaffold group. This group exhibited a signiﬁcantly higher rate of wound reduction, epithelial thickness, and collagen deposition during the postoperative period. These improvements were attributed to a signiﬁcantly higher expression level of the vascular endothelial growth factor gene (VEGF) in the scaffold of the treatment group. Fan et al. (2022) prepared PCL/gelatin nanoﬁber scaffolds loaded with silicate-based bioceramic particles using coaxial electrospinning to promote diabetic wound healing. The NAGEL particles were uniformly dispersed within the PCL/gelatin nanoﬁbers, and silica ions were actively released during scaffold degradation. The nanoﬁber scaffolds signiﬁcantly enhanced the adhesion, proliferation, and migration of human umbilical vein endothelial cells (HUVECs) and human keratinocytes (HaCaTs) in vitro. In vivo experiments were conducted using a rat diabetic wound model. The study revealed that the scaffolds can enhance the processes of angiogenesis, collagen deposition, and reepithelialization at the wound site by activating the epithelialmesenchymal transition (EMT) and endothelial-mesenchymal transition (End-MT) pathways in vivo, thereby inhibiting inﬂammatory responses (in Figure 6). Dwivedi et al. (2018) described a novel polyacrylic resin nanoﬁber scaffold capable of retaining gentamicin sulfate (GS) and recombinant human epidermal growth factor (rh-EGF). The scaffold was prepared by electrospinning and designed for wound healing in diabetic patients. GS was directly loaded into the polyacrylic resin through electrospinning, while rh-EGF was immobilized on the scaffold through surface modiﬁcation. In vitro cell assays demonstrated that the scaffolds exhibited antimicrobial activity equivalent to pure gentamicin powder. Moreover, in vivo experiments conducted on female diabetic mice showed that the scaffolds accelerated the healing process of dorsal wounds compared to the control group that healed naturally. Yin et al. (2016) proposed a novel therapeutic approach to convert macrophages from the M1-type to the M2-type. They fabricated drug-eluting nanoﬁber scaffolds through electrospinning and loaded them with monocyte chemotactic protein-1 (MCP-1) to achieve the desired effect. A stable release of MCP-1 from the scaffold for up to 3 days was observed. In vitro Anand et al. (2022) fabricated nanoﬁbrous scaffolds for diabetic wound healing using polyvinyl alcohol (PVA), sodium alginate (SA), silk ﬁbroin (SF), and loaded with acitretin (AT). The scaffolds demonstrated effective wound healing by maintaining moisture at the wound site. Furthermore, the scaffolds exhibited low cytotoxicity and promoted signiﬁcant cell migration in human keratinocytes (HaCat) cells, as demonstrated by cell viability analysis and scratch assays, respectively. The scaffolds demonstrated potent antibacterial activity against P. aeruginosa and S. aureus, as evidenced by successful in vitro tests. Moreover, in vivo studies conducted on a rat model of diabetes indicated a signiﬁcant improvement in wound healing when treated with the scaffold compared to the control group that received commercially available wound dressings. Teaima et al. (2022) reported on the preparation of a nanoﬁbrous scaffold loaded with linezolid using electrospinning. The scaffold was composed of a combination of polyurethane (TPU) and modiﬁed chitosan (CS). The morphological and mechanical characteristics of the scaffold were investigated. The results demonstrated that linezolid had no detrimental effect on the TPU/CS morphology. In vivo trials conducted on diabetic rats indicated that wound contraction and elastase levels increased in the group treated with the linezolid-loaded scaffold. There was a decrease in plasma nitric oxide and diminished glutathione activity, which facilitated the growth of new skin and remodeling of the vascular system. Xu et al. (2021) fabricated nanoﬁbrous scaffolds for the treatment of diabetic wounds and enhancement of diabetic wound healing by incorporating Phellodendron Bark extract (Compound Phellodendron Bark Liquid, CPL) into Silk Fibre (SF)/Poly (L-lactic-co-caprolactone) (PLCL) using electrospinning. SEM imaging revealed smooth and beadless nanoﬁbers, with a decrease in ﬁber diameter observed as the drug concentration increased. The scaffold demonstrated the ability to inhibit methicillin-resistant S. aureus (MRSA) and E. coli (Escherichia coli), enhance proliferation and adhesion of ﬁbroblasts in in vitro cellular experiments. Experiments conducted on diabetic mice demonstrated that CPL-loaded nanoﬁber scaffolds could increase TGF-β signaling pathway expression and collagen levels, while also inhibiting the expression of pro-inﬂammatory factors, effectively promoting diabetic wound healing. 4.4.2 Electrospun scaffolds loaded with inorganic nanoparticles, bioactive factors or special active cells Lv et al. (2017) utilized two-dimensional vermiculite nanosheets as a therapeutic agent to improve diabetic wounds by accelerating neovascularization through the activation of hypoxic-inducible factor 1α (HIF-1α) signaling. They subsequently incorporated the nanosheets into polycaprolactone to produce nanoﬁbrous scaffolds using electrospinning. The experiments demonstrated that the scaffolds can enhance neovascularization, re-epithelialization, and collagen formation in diabetic wounds, thereby facilitating the healing process. Liu et al. (2022) prepared an electrospun nanoﬁber scaffold composed of polycaprolactone (PCL)/gelatin/magnesium oxide (MgO) nanoparticles (PCL/gelatin/MgO) to promote wound Frontiers in Bioengineering and Biotechnology 13 frontiersin.org Jiang et al. 10.3389/fbioe.2024.1354286 FIGURE 6 (A) Representative wound images from each group on days 0, 3, 7, 10, and 14 after wound creation. On day 3, mild visible wound closure was observed in the treated rats compared to the untreated rats. The treatment groups with drug-loaded scaffolds exhibited signiﬁcantly faster wound closure on days 7 and 10 compared to the untreated groups and the treatment groups with pure scaffolds (Cam et al., 2021). (B) The effect of composite scaffolds containing NAG bioceramic particles on diabetic wound healing. Overview of the size change of excision wounds created in the dorsal skin of diabetic mice over different time periods and traces of wound bed closure for each treatment group in vivo. The light brown area indicates the wound area on day 0, and the blue area indicates the wound area on day n (n = 5, 7, 9, 11, and 13) (Fan et al., 2022). basic ﬁbroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF), bind to heparin through electrostatic interactions. This binding resulted in an acceleration of neovascularization. Elliott et al. (2019) reported the preparation of two nanoﬁber scaffolds through electrospinning. One scaffold was composed of collagen and periosteal proteins, while the other scaffold was composed of collagen and Recombinant Human Connective Tissue Growth Factor (CCN2). In vivo experiments were performed on a mouse model of diabetic wounds. Both the osteopontin/collagen and CCN2/collagen electrospun scaffolds enhanced the closure rate of excisional wounds compared to collagen alone or untreated wounds. On day 7, both scaffolds showed signiﬁcantly lower neutrophil inﬁltration and increased stromal cell inﬁltration compared to empty and collagen scaffolds. The vascularity of the wound bed increased signiﬁcantly on day 11. These scaffolds improved the healing rate of full-thickness skin lesions in diabetic mice while simultaneously enhancing angiogenesis. studies demonstrated that the electrospun scaffolds had no cytotoxic effects on human keratinocytes. Full-thickness excisional skin wounds were created on diabetic mice for the experiments. The wounds of mice treated with the drug-eluting scaffolds completely healed within 10 days, while those in the control group took 14 days. On day 3, mice treated with the drug-eluting scaffold showed a higher number of M2-type macrophages at the wound site. The signiﬁcant increase in macrophages is likely the reason for the accelerated wound healing observed (in Figure 7). Lee et al. (2015) designed a collagen/PLGA nanoﬁber scaffold incorporating glucophage through hybrid electrospinning for the treatment of diabetic wounds. The release rates of the drug were evaluated in vitro and in vivo using high-performance liquid chromatography (HPLC). The study utilized a rat model of diabetic wounds. The collagen content in diabetic rats treated with the scaffold was higher than that in control rats treated with commercial dressings, as matrix metalloproteinase 9 (MMP-9) was downregulated. This suggests that the scaffold has the ability to increase collagen content in the treatment of diabetic wounds, effectively promoting early wound healing. Vijayan et al. (2021) prepared collagen/PLGA/chitosan (CS) nanoﬁber scaffolds loaded with vascular growth factors. In vivo experiments were conducted on a mouse model with streptozotocininduced diabetes. The study showed that the vascular growth factors, Frontiers in Bioengineering and Biotechnology 5 Summary and outlook The global diagnosis rate of diabetes is rapidly increasing, leading to a signiﬁcant rise in diabetic foot ulcers (DFUs). To meet the needs of patients, continuous innovation in treatment options is necessary to overcome current limitations. Electrospinning scaffolds have shown 14 frontiersin.org Jiang et al. 10.3389/fbioe.2024.1354286 FIGURE 7 (A) Histopathological images comparing normal control, toxic control, F1 (non-crosslinked), and F2 (crosslinked) (Anand et al., 2022). (B) Evaluation of wound healing in diabetic C57/BL6 mice treated with different electrospun nanoﬁbrous scaffolds (panels from left to right represent the progression of wound healing over a 12-day period). Group 1: no treatment (negative control); group 2: 0.1% GS ointment (positive control); group 3: Eudragit RL/RS 100 scaffold without GS and rhEGF; group 4: Eudragit RL/RS 100 scaffold with GS and rhEGF; group 5: Eudragit RL/RS 100 scaffold with GS without rhEGF. (B) Percentage of open wound area (as a percentage of the initial area) over the 12-day treatment period for each group (Dwivedi et al., 2018). (C) Representative histology images of wound sites on day 10. DES: Drug-eluting scaffold; NES: Non-eluting scaffold; Control. The DES group exhibited the most favorable recovery from the cutaneous wound, characterized by a thick epithelial layer (Yin et al., 2016). models. However, animal experiments have limitations when translating to human patients. Overcoming these challenges is crucial to facilitate future clinical trials, including the reduction of toxic residues from organic solvents in nanoﬁbers and minimizing adverse effects associated with drug release. Additionally, industrial production of electrospinning scaffolds is of great importance. Continuous exploration of improving production efﬁciency, standardizing large-scale production, and fabricating complex nanostructures is needed. Further understanding of the treatment mechanisms of diabetic wound healing and the development of electrospinning technology will contribute to advancements in diabetic wound treatment. Moreover, the introduction of electrospraying, a sister technique to electrospinning, can further expand the possibilities for treating diabetic wounds (Han et al., 2020; He et al., 2022; Zhou et al., 2023a; Chen et al., 2023; Ji et al., 2023; Sun et al., 2023; Xu et al., 2023; Yu and Xu, 2023; Yu and Zhou, 2023). This, combined with research focus and improved patient promising effectiveness in diabetic wound healing and DFU treatment due to their similarity in structure and composition to the extracellular matrix (ECM). These scaffolds provide a conducive environment for cell adhesion, growth, and facilitate skin tissue healing and neovascularization. This article reviewed the pathological differences in treating normal and diabetic wounds, discussed the pathogenesis of DFUs, and highlighted the urgent need for new treatments. Various electrospun scaffolds with different ﬂuids and structures were introduced, along with their applications in diabetic wounds. Most of these applications promote the regeneration of diabetic wounds through drug-loaded scaffolds or the inherent properties of the electrospun scaffolds, such as stimulating cell migration, promoting angiogenesis, reducing inﬂammation and infection, and facilitating tissue re-epithelization. Currently, the therapeutic effects of these electrospun nanoﬁber scaffolds on diabetic wounds are mainly studied in vivo using diabetic rat Frontiers in Bioengineering and Biotechnology 15 frontiersin.org Jiang et al. 10.3389/fbioe.2024.1354286 Conﬂict of interest compliance, holds great promise for improving the current status of diabetic wound treatment. The authors declare that the research was conducted in the absence of any commercial or ﬁnancial relationships that could be construed as a potential conﬂict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the ﬁnal decision. Author contributions XJ: Conceptualization, Formal Analysis, Investigation, Methodology, Software, Writing–original draft. YZ: Data curation, Writing–original draft. CL: Visualization, Writing–review and editing. KW: Funding acquisition, Investigation, Resources, Supervision, Writing–review and editing. D-GY: Resources, Supervision, Writing–review and editing. Publisher’s note All claims expressed in this article are solely those of the authors and do not necessarily represent those of their afﬁliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher. Funding The author(s) declare that no ﬁnancial support was received for the research, authorship, and/or publication of this article. References granulation tissue formation during wound healing. Biomaterials 81, 157–168. doi:10.1016/j.biomaterials.2015.12.003 Abbaszadeh, M., Meybodi, S. M., Zarei, A., Khorasgani, E. M., Heravi, H. M., and Kasaiyan, N. (2022). Cellulose acetate nanoﬁbrous wound dressings loaded with 1% probucol alleviate oxidative stress and promote diabetic wound healing: an in vitro and in vivo study. Cellulose 29, 5359–5374. doi:10.1007/s10570-022-04560-3 Derakhshan, M. A., Nazeri, N., Khoshnevisan, K., Heshmat, R., and Omidfar, K. (2022). Three-layered PCL-collagen nanoﬁbers containing melilotus ofﬁcinalis extract for diabetic ulcer healing in a rat model. J. Diabetes Metab. Disord. 21, 313–321. doi:10. 1007/s40200-022-00976-7 Abdelbasset, W. K., Elkholi, S. M., Ismail, K. A., Al-Ghamdi, H. S., Mironov, S., Ridha, H. S. H., et al. (2022). Mequinol-loaded carboxymethyl cellulose/chitosan electrospun wound dressing as a potential candidate to treat diabetic wounds. Cellulose 29, 7863–7881. doi:10.1007/s10570-022-04753-w Ding, Y., Dou, C., Chang, S., Xie, Z., Yu, D.-G., Liu, Y., et al. (2020). Core-shell Eudragit S100 nanoﬁbers prepared via triaxial electrospinning to provide a colontargeted extended drug release. Polymers 12, 2034. doi:10.3390/polym12092034 Ahmed, R., Tariq, M., Ali, I., Asghar, R., Khanam, P. N., Augustine, R., et al. (2018). Novel electrospun chitosan/polyvinyl alcohol/zinc oxide nanoﬁbrous mats with antibacterial and antioxidant properties for diabetic wound healing. Int. J. Biol. Macromol. 120, 385–393. doi:10.1016/j.ijbiomac.2018.08.057 Dong, Y., Fu, S., Yu, J., Li, X., and Ding, B. (2023). Emerging smart micro/nanoﬁberbased materials for next-generation wound dressings. Adv. Funct. Mater. 2311199. doi:10.1002/adfm.202311199 Al-Dhahebi, A. M., Ling, J., Krishnan, S. G., Yousefzadeh, M., Elumalai, N. K., Saheed, M. S. M., et al. (2022). Electrospinning research and products: the road and the way forward. Appl. Phys. Rev. 9, 011319. doi:10.1063/5.0077959 Duan, H., Chen, H., Qi, C., Lv, F., Wang, J., Liu, Y., et al. (2024). A novel electrospun nanoﬁber system with PEGylated paclitaxel nanocrystals enhancing the transmucus permeability and in situ retention for an efﬁcient cervicovaginal cancer therapy. Int. J. Pharm. 650, 123660. doi:10.1016/j.ijpharm.2023.123660 Anand, S., Rajinikanth, P. S., Arya, D. K., Pandey, P., Gupta, R. K., Sankhwar, R., et al. (2022). Multifunctional biomimetic nanoﬁbrous scaffold loaded with asiaticoside for rapid diabetic wound healing. Pharmaceutics 14, 273. doi:10.3390/pharmaceutics14020273 Dwivedi, C., Pandey, I., Pandey, H., Patil, S., Mishra, S. B., Pandey, A. C., et al. (2018). In vivo diabetic wound healing with nanoﬁbrous scaffolds modiﬁed with gentamicin and recombinant human epidermal growth factor. J. Biomed. Mater. Res. 106, 641–651. doi:10.1002/jbm.a.36268 Aschner, P., Karuranga, S., James, S., Simmons, D., Basit, A., Shaw, J. E., et al. (2021). The International Diabetes Federation’s guide for diabetes epidemiological studies. Diabetes Res. Clin. Pract. 172, 108630. doi:10.1016/j.diabres.2020.108630 El-Lakany, S. A., Kamoun, E. A., Abd-Elhamid, A., Aly, R. G., Samy, W. M., and Elgindy, N. A. (2020). Graphene oxide crosslinked-zein nanoﬁbrous scaffolds for prominent Cu-adsorption as tissue regeneration promoters in diabetic rats: nanoﬁbers optimization and in vivo assessment. Int. J. Pharm. 590, 119919. doi:10. 1016/j.ijpharm.2020.119919 Augustine, R., Zahid, A. A., Hasan, A., Wang, M., and Webster, T. J. (2019). CTGF loaded electrospun dual porous core-shell membrane for diabetic wound healing. Int. J. Nanomed. 14, 8573–8588. doi:10.2147/IJN.S224047 Behm, B., Babilas, P., Landthaler, M., and Schreml, S. (2012). Cytokines, chemokines and growth factors in wound healing. J. Eur. Acad. Dermatol. Venereol. 26, 812–820. doi:10.1111/j.1468-3083.2011.04415.x Elliott, C. G., Wang, J., Walker, J. T., Michelsons, S., Dunmore-Buyze, J., Drangova, M., et al. (2019). Periostin and CCN2 scaffolds promote the wound healing response in the skin of diabetic mice. Tissue Eng. Part A 25, 1326–1339. doi:10.1089/ten.tea.2018. 0268 Cam, M. E., Ertas, B., Alenezi, H., Hazar-Yavuz, A. N., Cesur, S., Ozcan, G. S., et al. (2021). Accelerated diabetic wound healing by topical application of combination oral antidiabetic agents-loaded nanoﬁbrous scaffolds: an in vitro and in vivo evaluation study. Mat. Sci. Eng. c-mater. Biol. Appl. 119, 111586. doi:10. 1016/j.msec.2020.111586 ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., et al. (2023). Classiﬁcation and diagnosis of diabetes: Standards of Care in diabetes—2023. Diabetes Care 46, S19–S40. doi:10.2337/dc23-S002 Chakraborty, S., Liao, I.-C., Adler, A., and Leong, K. W. (2009). Electrohydrodynamics: a facile technique to fabricate drug delivery systems. Adv. Drug Deliv. Rev. 61, 1043–1054. doi:10.1016/j.addr.2009.07.013 Fan, Y., Zhi, Y., He, M., Ahmadzadeh, B., and Rohani, S. (2022). Cellulose acetate/ Plerixafor wound dressings for transplantation of menstrual blood stem cells: potential treatment modality for diabetic wounds. J. Drug Deliv. Sci. Technol. 71, 103319. doi:10. 1016/j.jddst.2022.103319 Chen, S., Zhou, J., Fang, B., Ying, Y., Yu, D., and He, H. (2023). Three EHDA processes from a detachable spinneret for fabricating drug fast dissolution composites. Macro Mater. Eng 2300361. doi:10.1002/mame.202300361 Feldman, E. L., Callaghan, B. C., Pop-Busui, R., Zochodne, D. W., Wright, D. E., Bennett, D. L., et al. (2019). Diabetic neuropathy. Nat. Rev. Dis. Prim. 5, 41. doi:10.1038/ s41572-019-0092-1 Chen, X., Liu, Y., and Liu, P. (2024). Electrospun core–sheath nanoﬁbers with a cellulose acetate coating for the synergistic release of zinc ion and drugs. Mol. Pharm. 21, 173–182. doi:10.1021/acs.molpharmaceut.3c00703 Felgueiras, H. P., and Amorim, M. T. P. (2017). Functionalization of electrospun polymeric wound dressings with antimicrobial peptides. Colloid Surf. B-Biointerfaces 156, 133–148. doi:10.1016/j.colsurfb.2017.05.001 da Silva, L. P., Reis, R. L., Correlo, V. M., and Marques, A. P. (2019). “Hydrogel-based strategies to advance therapies for chronic skin wounds,” in Annual review of biomedical engineering. Editor M. L. Yamush (Palo Alto: Annual Reviews), Vol 21, 145–169. doi:10. 1146/annurev-bioeng-060418-052422 Futrega, K., King, M., Lott, W. B., and Doran, M. R. (2014). Treating the whole not the hole: necessary coupling of technologies for diabetic foot ulcer treatment. Trends Mol. Med. 20, 137–142. doi:10.1016/j.molmed.2013.12.004 Gao, D., Zhang, Y., Bowers, D. T., Liu, W., and Ma, M. (2021). Functional hydrogels for diabetic wound management. Apl. Bioeng. 5, 031503. doi:10.1063/5.0046682 Decker, C. G., Wang, Y., Paluck, S. J., Shen, L., Loo, J. A., Levine, A. J., et al. (2016). Fibroblast growth factor 2 dimer with. superagonist in vitro activity improves Frontiers in Bioengineering and Biotechnology 16 frontiersin.org Jiang et al. 10.3389/fbioe.2024.1354286 Gao, Z., Wang, Q., Yao, Q., and Zhang, P. (2022). Application of electrospun nanoﬁber membrane in the treatment of diabetic wounds. Pharmaceutics 14, 6. doi:10.3390/pharmaceutics14010006 Jintao, Y. (2022). Idebenone-loaded wound dressings promote diabetic wound healing through downregulation of Il1b, Nfkb genes and upregulation of Fgf2 gene. Res. Vet. Sci. 151, 128–137. doi:10.1016/j.rvsc.2022.07.002 Gholipour-Kanani, A., Bahrami, S. H., and Rabbani, S. (2016). Effect of novel blend nanoﬁbrous scaffolds on diabetic wounds healing. IET Nanobiotechnol 10, 1–7. doi:10. 1049/iet-nbt.2014.0066 Junker, J. P. E., Kamel, R. A., Caterson, E. J., and Eriksson, E. (2013). Clinical impact upon wound healing and inﬂammation in moist, wet, and dry environments. Adv. Wound Care (New Rochelle) 2, 348–356. doi:10.1089/wound.2012.0412 Glover, K., Stratakos, A. C., Varadi, A., and Lamprou, D. A. (2021). 3D scaffolds in the treatment of diabetic foot ulcers: new trends vs conventional approaches. Int. J. Pharm. 599, 120423. doi:10.1016/j.ijpharm.2021.120423 Kakunuri, M., Khandelwal, M., Sharma, C. S., and Eichhorn, S. J. (2017). Fabrication of bio-inspired hydrophobic self-assembled electrospun nanoﬁber based hierarchical structures. Mat. Lett. 196, 339–342. doi:10.1016/j.matlet.2017.03.094 Gumy, L. F., Bampton, E. T. W., and Tolkovsky, A. M. (2008). Hyperglycaemia inhibits Schwann cell proliferation and migration and restricts regeneration of axons and Schwann cells from adult murine DRG. Mol. Cell. Neurosci. 37, 298–311. doi:10. 1016/j.mcn.2007.10.004 Kamal, R., Razzaq, A., Shah, K. A., Khan, Z. U., Khan, N. U., Menaa, F., et al. (2022). Evaluation of cephalexin-loaded PHBV nanoﬁbers for MRSA-infected diabetic foot ulcers treatment. J. Drug Deliv. Sci. Technol. 71, 103349. doi:10.1016/j.jddst.2022.103349 Kang, S., Hou, S., Chen, X., Yu, D.-G., Wang, L., Li, X., et al. (2020). Energy-saving electrospinning with a concentric teﬂon-core rod spinneret to create medicated nanoﬁbers. Polymers 12, 2421. doi:10.3390/polym12102421 Guo, L., Guan, N., Miao, W., Zhao, W., and Li, Q. (2022). An electrospun scaffold loaded with an enteromorpha polysaccharide for accelerated wound healing in diabetic mice. Mar. Drugs 20, 95. doi:10.3390/md20020095 Ke, P., Jiao, X.-N., Ge, X.-H., Xiao, W.-M., and Yu, B. (2014). From macro to micro: structural biomimetic materials by electrospinning. RSC Adv. 4, 39704–39724. doi:10. 1039/c4ra05098c Gupta, P., and Wilkes, G. L. (2003). Some investigations on the ﬁber formation by utilizing a side-by-side bicomponent electrospinning approach. Polymer 44, 6353–6359. doi:10.1016/S0032-3861(03)00616-5 Han, D., and Steckl, A. J. (2019). Coaxial electrospinning formation of complex polymer ﬁbers and their applications. ChemPlusChem 84, 1453–1497. doi:10.1002/cplu. 201900281 Kellar, R. S., Diller, R. B., Tabor, A. J., Dominguez, D. D., Audet, R. G., Bardsley, T. A., et al. (2020). Improved wound closure rates and mechanical properties resembling native skin in murine diabetic wounds treated with a Tropoelastin and collagen wound healing device. J. Diabetes Clin. Res. 2, 86–99. doi:10.33696/diabetes.1.024 Han, Y., Jiang, Y., Li, Y., Wang, M., Fan, T., Liu, M., et al. (2019). An aligned porous electrospun ﬁbrous scaffold with embedded asiatic acid for accelerating diabetic wound healing. J. Mat. Chem. B 7, 6125–6138. doi:10.1039/c9tb01327j Kim, H., Lohani, P. C., Bhattarai, D. P., Tiwari, A. P., and Kim, H. Y. (2022). Phytic acidenhanced electrospun PCL-polypyrrole nanoﬁbrous mat: preparation, characterization, and mechanism. Macromol. Res. 30, 791–798. doi:10.1007/s13233-022-0086-9 Han, Y., Xu, Y., Zhang, S., Li, T., Ramakrishna, S., and Liu, Y. (2020). Progress of improving mechanical strength of electrospun nanoﬁbrous membranes. Macromol. Mat. Eng. 305, 2000230. doi:10.1002/mame.202000230 Kim, H. J., Pant, H. R., Amarjargal, A., and Kim, C. S. (2013). Incorporation of silverloaded ZnO rods into electrospun nylon-6 spider-web-like nanoﬁbrous mat using hydrothermal process. Colloid Surf. a-physicochem. Eng. Asp. 434, 49–55. doi:10.1016/j. colsurfa.2013.05.038 He, H., Wu, M., Zhu, J., Yang, Y., Ge, R., and Yu, D.-G. (2022). Engineered spindles of little molecules around electrospun nanoﬁbers for biphasic drug release. Adv. Fiber Mat. 4, 305–317. doi:10.1007/s42765-021-00112-9 Kim, H. N., Hong, Y., Kim, M. S., Kim, S. M., and Suh, K.-Y. (2012). Effect of orientation and density of nanotopography in dermal wound healing. Biomaterials 33, 8782–8792. doi:10.1016/j.biomaterials.2012.08.038 Hinz, B. (2016). The role of myoﬁbroblasts in wound healing. Curr. Res. Transl. Med. 64, 171–177. doi:10.1016/j.retram.2016.09.003 Kim, S., and Kwon, J. (2014). Thymosin beta 4 improves dermal burn wound healing via downregulation of receptor of advanced glycation end products in db/db mice. Biochim. Biophys. Acta-Gen. Subj. 1840, 3452–3459. doi:10.1016/j.bbagen.2014.09.013 Holl, J., Kowalewski, C., Zimek, Z., Fiedor, P., Kaminski, A., Oldak, T., et al. (2021). Chronic diabetic wounds and their treatment with skin substitutes. Cells 10, 655. doi:10. 3390/cells10030655 Kong, H. Y., Liu, H. Y., and He, J. H. (2014). High orientation ordered nanoﬁbers fabricated by electrospinning. Adv. Mater. Res. 843, 21–25. doi:10.4028/www.scientiﬁc. net/AMR.843.21 Hu, Y., Wu, B., Xiong, Y., Tao, R., Panayi, A. C., Chen, L., et al. (2021). Cryogenic 3D printed hydrogel scaffolds loading exosomes accelerate diabetic wound healing. Chem. Eng. J. 426, 130634. doi:10.1016/j.cej.2021.130634 Lau, K., Paus, R., Tiede, S., Day, P., and Bayat, A. (2009). Exploring the role of stem cells in cutaneous wound healing. Exp. Dermatol. 18, 921–933. doi:10.1111/j.1600-0625. 2009.00942.x Huang, S.-M., Wu, C.-S., Chiu, M.-H., Wu, C.-H., Chang, Y.-T., Chen, G.-S., et al. (2019). High glucose environment induces M1 macrophage polarization that impairs keratinocyte migration via TNF-α: an important mechanism to delay the diabetic wound healing. J. Dermatol. Sci. 96, 159–167. doi:10.1016/j. jdermsci.2019.11.004 Lee, C.-H., Chang, S.-H., Chen, W.-J., Hung, K.-C., Lin, Y.-H., Liu, S.-J., et al. (2015). Augmentation of diabetic wound healing and enhancement of collagen content using nanoﬁbrous glucophage-loaded collagen/PLGA scaffold membranes. J. Colloid Interface Sci. 439, 88–97. doi:10.1016/j.jcis.2014.10.028 Huang, S.-M., Wu, C.-S., Chiu, M.-H., Yang, H.-J., Chen, G.-S., and Lan, C.-C. E. (2017). High-glucose environment induced intracellular O-GlcNAc glycosylation and reduced galectin-7 expression in keratinocytes: implications on impaired diabetic wound healing. J. Dermatol. Sci. 87, 168–175. doi:10.1016/j.jdermsci.2017.04.014 Lee, C.-H., Hsieh, M.-J., Roth, J. G., Fu, X., Lu, C.-H., Hung, K.-C., et al. (2022). Hybrid core-shell nanoﬁbrous scaffolds/stents deliver angiotensin II receptor blocker to treat diabetic artery disease. ACS Appl. Polym. Mat. 4, 4199–4207. doi:10.1021/acsapm. 2c00186 Huang, X., Jiang, W., Zhou, J., Yu, D.-G., and Liu, H. (2022a). The applications of ferulic-acid-loaded ﬁbrous ﬁlms for fruit preservation. Polymers 14, 4947. doi:10.3390/ polym14224947 Lee, C.-H., Hung, K.-C., Hsieh, M.-J., Chang, S.-H., Juang, J.-H., Hsieh, I.-C., et al. (2020a). Core-shell insulin-loaded nanoﬁbrous scaffolds for repairing diabetic wounds. Nanomed.-Nanotechnol. Biol. Med. 24, 102123. doi:10.1016/j.nano.2019.102123 Huang, X., Wang, Q., Mao, R., Wang, Z., Shen, S. G. F., Mou, J., et al. (2022b). Twodimensional nanovermiculite and polycaprolactone electrospun ﬁbers composite scaffolds promoting diabetic wound healing. J. Nanobiotechnol. 20, 343. doi:10.1186/ s12951-022-01556-w Lee, C.-H., Liu, K.-S., Cheng, C.-W., Chan, E.-C., Hung, K.-C., Hsieh, M.-J., et al. (2020b). Codelivery of sustainable antimicrobial agents and platelet-derived growth factor via biodegradable nanoﬁbers for repair of diabetic infectious wounds. ACS Infect. Dis. 6, 2688–2697. doi:10.1021/acsinfecdis.0c00321 Hussein, M. A. M., Gunduz, O., Sahin, A., Grinholc, M., El-Sherbiny, I. M., and Megahed, M. (2022). Dual spinneret electrospun polyurethane/PVA-gelatin nanoﬁbrous scaffolds containing cinnamon essential oil and nanoceria for chronic diabetic wound healing: preparation, physicochemical characterization and in-vitro evaluation. Molecules 27, 2146. doi:10.3390/molecules27072146 Lei, L., Huang, W., Liu, K., Liu, X., Dai, M., Liu, Z., et al. (2022). Trilazad mesylateloaded electrospun cellulose acetate nanoﬁbrous wound dressings promote diabetic wound healing by modulation of immune response and protection against oxidative damage. J. Drug Deliv. Sci. Technol. 69, 102863. doi:10.1016/j.jddst.2021.102863 Inai, R., Kotaki, M., and Ramakrishna, S. (2005). Deformation behavior of electrospun poly(L-lactide-Co-ε-Caprolactone) nonwoven membranes under uniaxial tensile loading. J. Polym. Sci. B Polym. Phys. 43, 3205–3212. doi:10.1002/polb.20457 Li, J., Du, Q., Wan, J., Yu, D. G., Tan, F., and Tang, X. (2024). Improved synergistic anticancer action of quercetin and tamoxifen citrate supported by an electrospun complex nanostructure. Mater. Des. 238, 112657. doi:10.1016/j.matdes.2024.112657 Jeckson, T. A., Neo, Y. P., Sisinthy, S. P., and Gorain, B. (2021). Delivery of therapeutics from layer-by-layer electrospun nanoﬁber matrix for wound healing: an update. J. Pharm. Sci. 110, 635–653. doi:10.1016/j.xphs.2020.10.003 Li, R., Cheng, Z., Yu, X., Wang, S., Han, Z., and Kang, L. (2019). Preparation of antibacterial PCL/PVP-AgNP Janus nanoﬁbers by uniaxial electrospinning. Mat. Lett. 254, 206–209. doi:10.1016/j.matlet.2019.07.075 Ji, Y., Zhao, H., Liu, H., Zhao, P., and Yu, D.-G. (2023). Electrosprayed stearic-acidcoated ethylcellulose microparticles for an improved sustained release of anticancer drug. Gels 9, 700. doi:10.3390/gels9090700 Liang, Y., Liang, Y. P., Zhang, H., and Guo, B. (2022). Antibacterial biomaterials for skin wound dressing. Asian J. Pharm. Sci. 17, 353–384. doi:10.1016/j.ajps.2022.01.001 Jiang, Y., Han, Y., Wang, J., Lv, F., Yi, Z., Ke, Q., et al. (2019). Space-oriented nanoﬁbrous scaffold with silicon-doped amorphous calcium phosphate nanocoating for diabetic wound healing. ACS Appl. Bio Mat. 2, 787–795. doi:10.1021/acsabm.8b00657 Liu, M., Wang, R., Liu, J., Zhang, W., Liu, Z., Lou, X., et al. (2022). Incorporation of magnesium oxide nanoparticles into electrospun membranes improves pro-angiogenic activity and promotes diabetic wound healing. Biomater. Adv. 133, 112609. doi:10.1016/ j.msec.2021.112609 Jiang, Y., Li, Y., Li, J., Han, Y., Zhang, P., Yi, Z., et al. (2020). A mussel-inspired extracellular matrix-mimicking composite scaffold for diabetic wound healing. ACS Appl. Bio Mat. 3, 4052–4061. doi:10.1021/acsabm.0c00143 Liu, Y., Zhou, S., Gao, Y., and Zhai, Y. (2019). Electrospun nanoﬁbers as a wound dressing for treating diabetic foot ulcer. Asian J. Pharm. Sci. 14, 130–143. doi:10.1016/j. ajps.2018.04.004 Frontiers in Bioengineering and Biotechnology 17 frontiersin.org Jiang et al. 10.3389/fbioe.2024.1354286 Lv, F., Wang, J., Xu, P., Han, Y., Ma, H., Xu, H., et al. (2017). A conducive bioceramic/ polymer composite biomaterial for diabetic wound healing. Acta Biomater. 60, 128–143. doi:10.1016/j.actbio.2017.07.020 Rathore, P., and Schiffman, J. D. (2021). Beyond the single-nozzle: coaxial electrospinning enables innovative nanoﬁber chemistries, geometries, and applications. ACS Appl. Mat. Interfaces 13, 48–66. doi:10.1021/acsami.0c17706 Lv, H., Liu, Y., Bai, Y., Shi, H., Zhou, W., Chen, Y., et al. (2023a). Recent combinations of electrospinning with photocatalytic technology for treating polluted water. Catalysts 13, 758. doi:10.3390/catal13040758 Ren, X., Han, Y., Wang, J., Jiang, Y., Yi, Z., Xu, H., et al. (2018). An aligned porous electrospun ﬁbrous membrane with controlled drug delivery - an efﬁcient strategy to accelerate diabetic wound healing with improved angiogenesis. Acta Biomater. 70, 140–153. doi:10.1016/j.actbio.2018.02.010 Lv, H., Liu, Y., Zhao, P., Bai, Y., Cui, W., Shen, S., et al. (2023b). Insight into the superior piezophotocatalytic performance of BaTiO3//ZnO Janus nanoﬁbrous heterostructures in the treatment of multi-pollutants from water. Appl. Catal. B Environ. 330, 122623. doi:10.1016/j.apcatb.2023.122623 Roep, B. O., Wheeler, D. C. S., and Peakman, M. (2019). Antigen-based immune modulation therapy for type 1 diabetes: the era of precision medicine. Lancet Diabetes & Endocrinol. 7, 65–74. doi:10.1016/S2213-8587(18)30109-8 Lv, H., Zhao, M., Li, Y., Li, K., Chen, S., Zhao, W., et al. (2022). Electrospun chitosanpolyvinyl alcohol nanoﬁber dressings loaded with bioactive ursolic acid promoting diabetic wound healing. Nanomaterials 12, 2933. doi:10.3390/nano12172933 Rojano, R. M., Mendez, S., Lucor, D., Ranc, A., Giansily-Blaizot, M., Schved, J.-F., et al. (2019). Kinetics of the coagulation cascade including the contact activation system: sensitivity analysis and model reduction. Biomech. Model. Mechanobiol. 18, 1139–1153. doi:10.1007/s10237-019-01134-4 Maashi, M. S., Felemban, S. G., Almasmoum, H. A., and Jarahian, M. (2023). Nicaraven-loaded electrospun wound dressings promote diabetic wound healing via proangiogenic and immunomodulatory functions: a preclinical investigation. Drug Deliv. Transl. Res. 13, 222–236. doi:10.1007/s13346-022-01176-9 Sadati, S. M., Radfar, M., Hamidi, A. K., Abdollahi, M., Qorbani, M., Esfahani, E. N., et al. (2018). Association between the polymorphism of Glu298Asp in exon 7 of the eNOS gene with foot ulcer and oxidative stress in adult patients with type 2 diabetes. Can. J. Diabetes 42, 18–22. doi:10.1016/j.jcjd.2017.03.001 Madhukiran, D. R., Jha, A., Kumar, M., Ajmal, G., Bonde, G. V., and Mishra, B. (2021). Electrospun nanoﬁber-based drug delivery platform: advances in diabetic foot ulcer management. Expert Opin. Drug Deliv. 18, 25–42. doi:10.1080/17425247.2021. 1823966 Sahu, B., Prusty, A., and Tudu, B. (2018). Total contact casting versus traditional dressing in diabetic foot ulcers. J. Orthop. Surg. 26, 230949901880248. doi:10.1177/ 2309499018802486 Maouia, A., Rebetz, J., Kapur, R., and Semple, J. W. (2020). The immune nature of platelets revisited. Transf. Med. Rev. 34, 209–220. doi:10.1016/j.tmrv.2020.09.005 Samadian, H., Zamiri, S., Ehterami, A., Farzamfar, S., Vaez, A., Khastar, H., et al. (2020). Electrospun cellulose acetate/gelatin nanoﬁbrous wound dressing containing berberine for diabetic foot ulcer healing: in vitro and in vivo studies. Sci. Rep. 10, 8312. doi:10.1038/s41598-020-65268-7 Marston, W. A., Hanft, J., Norwood, P., and Pollak, R. (2003). The efﬁcacy and safety of dermagraft in improving the healing of chronic diabetic foot ulcers. Diabetes Care 26, 1701–1705. doi:10.2337/diacare.26.6.1701 Sanhueza, C., Hermosilla, J., Bugallo-Casal, A., Da Silva-Candal, A., Taboada, C., Millan, R., et al. (2021). One-step electrospun scaffold of dual-sized gelatin/poly-3hydroxybutyrate nano/microﬁbers for skin regeneration in diabetic wound. Mat. Sci. Eng. c-mater. Biol. Appl. 119, 111602. doi:10.1016/j.msec.2020.111602 McDermott, K., Fang, M., Boulton, A. J. M., Selvin, E., and Hicks, C. W. (2023). Etiology, epidemiology, and disparities in the burden of diabetic foot ulcers. Diabetes Care 46, 209–221. doi:10.2337/dci22-0043 Schreml, S., Szeimies, R. M., Prantl, L., Karrer, S., Landthaler, M., and Babilas, P. (2010). Oxygen in acute and chronic wound healing. Br. J. Dermatol. 163, 257–268. doi:10.1111/j.1365-2133.2010.09804.x Megallaa, M. H., Ismail, A. A., Zeitoun, M. H., and Khalifa, M. S. (2019). Association of diabetic foot ulcers with chronic vascular diabetic complications in patients with type 2 diabetes. Diabetes Metab. syndr.-clin. Res. Rev. 13, 1287–1292. doi:10.1016/j.dsx.2019. 01.048 Sell, S. A., Wolfe, P. S., Garg, K., McCool, J. M., Rodriguez, I. A., and Bowlin, G. L. (2010). The use of natural polymers in tissue engineering: a focus on electrospun extracellular matrix analogues. Polymers 2, 522–553. doi:10.3390/polym2040522 Mellor, L. F., Huebner, P., Cai, S., Mohiti-Asli, M., Taylor, M. A., Spang, J., et al. (2017). Fabrication and evaluation of electrospun, 3D-bioplotted, and combination of electrospun/3D-bioplotted scaffolds for tissue engineering applications. Biomed. Res. Int. 2017, 1–9. doi:10.1155/2017/6956794 Si, Y., Shi, S., and Hu, J. (2023). Applications of electrospinning in human health: from detection, protection, regulation to reconstruction. Nano Today 48, 101723. doi:10. 1016/j.nantod.2022.101723 Mohammadi, M. A., Rostami, M., Beikzadeh, S., Raeisi, M., Tabibiazar, M., and Youseﬁ, M. (2019). Electrospun nanoﬁbers as advanced antibacterial platforms: a review of recent studies. Int. J. Pharm.l Sci. Res. 10, 463–473. doi:10.13040/IJPSR.0975-8232. 10(2).463-73 Sinegre, T., Teissandier, D., Milenkovic, D., Morand, C., and Lebreton, A. (2019). Epicatechin inﬂuences primary hemostasis, coagulation and ﬁbrinolysis. Food Funct. 10, 7291–7298. doi:10.1039/c9fo00816k Monteiro-Soares, M., Hamilton, E. J., Russell, D. A., Srisawasdi, G., Boyko, E. J., Mills, J. L., et al. (2023). Guidelines on the classiﬁcation of foot ulcers in people with diabetes (IWGDF 2023 update). Diabetes Metab. Res., e3648. doi:10.1002/dmrr.3648 Singh, C., Wong, C. S., and Wang, X. (2015). Medical textiles as vascular implants and their success to mimic natural arteries. J. Funct. Biomater. 6, 500–525. doi:10.3390/jfb6030500 Singh, S. K., Sahay, R. K., and Krishna, A. (2008). Oxidative stress in diabetic foot ulcer. Diabetes & Metabolic Syndrome Clin. Res. Rev. 2, 109–113. doi:10.1016/j.dsx.2008.02.003 Nagiah, N., Murdock, C. J., Bhattacharjee, M., Nair, L., and Laurencin, C. T. (2020). Development of tripolymeric triaxial electrospun ﬁbrous matrices for dual drug delivery applications. Sci. Rep. 10, 609. doi:10.1038/s41598-020-57412-0 Stojanov, S., and Berlec, A. (2020). Electrospun nanoﬁbers as carriers of microorganisms, stem cells, proteins, and nucleic acids in therapeutic and other applications. Front. Bioeng. Biotechnol. 8, 130. doi:10.3389/fbioe.2020.00130 Nguyen, T. T., Ding, D., Wolter, W. R., Perez, R. L., Champion, M. M., Mahasenan, K. V., et al. (2018). Validation of matrix metalloproteinase-9 (MMP-9) as a novel target for treatment of diabetic foot ulcers in humans and discovery of a potent and selective small-molecule MMP-9 inhibitor that accelerates healing. J. Med. Chem. 61, 8825–8837. doi:10.1021/acs.jmedchem.8b01005 Su, Y., Mainardi, V. L., Wang, H., McCarthy, A., Zhang, Y. S., Chen, S., et al. (2020). Dissolvable microneedles coupled with nanoﬁber dressings eradicate bioﬁlms via effectively delivering a database-designed antimicrobial peptide. ACS Nano 14, 11775–11786. doi:10.1021/acsnano.0c04527 Pan, H., Shi, C., Yang, R., Xi, G., Lu, C., Yang, X., et al. (2021). Controlled release of KGF2 for regulation of wound healing by KGF-2 complexed with “lotus seedpod surface-like” porous microspheres. J. Mat. Chem. B 9, 4039–4049. doi:10.1039/d1tb00148e Sun, H., Saeedi, P., Karuranga, S., Pinkepank, M., Ogurtsova, K., Duncan, B. B., et al. (2022). IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res. Clin. Pract. 183, 109119. doi:10.1016/j.diabres.2021.109119 Pant, B., Park, M., and Park, S.-J. (2019). Drug delivery applications of core-sheath nanoﬁbers prepared by coaxial electrospinning: a review. Pharmaceutics 11, 305. doi:10. 3390/pharmaceutics11070305 Sun, L., Gao, W., Fu, X., Shi, M., Xie, W., Zhang, W., et al. (2018). Enhanced wound healing in diabetic rats by nanoﬁbrous scaffolds mimicking the basketweave pattern of collagen ﬁbrils in native skin. Biomater. Sci. 6, 340–349. doi:10.1039/c7bm00545h Peng, Y., He, D., Ge, X., Lu, Y., Chai, Y., Zhang, Y., et al. (2021). Construction of heparin-based hydrogel incorporated with Cu5.4O ultrasmall nanozymes for wound healing and inﬂammation inhibition. Bioact. Mat. 6, 3109–3124. doi:10.1016/j. bioactmat.2021.02.006 Sun, L., Zhou, J., Chen, Y., Yu, D.-G., and Liu, P. (2023). A combined electrohydrodynamic atomization method for preparing nanoﬁber/microparticle hybrid medicines. Front. Bioeng. Biotechnol. 11, 1308004. doi:10.3389/fbioe.2023.1308004 Peter-Riesch, B. (2016). The diabetic foot: the never-ending challenge. Endocr. Dev. 31, 108–134. doi:10.1159/000439409 Surucu, S., and Sasmazel, H. T. (2016). Development of core-shell coaxially electrospun composite PCL/chitosan scaffolds. Int. J. Biol. Macromol. 92, 321–328. doi:10.1016/j.ijbiomac.2016.07.013 Qian, C. H., Liu, Y. B., Chen, S., Zhang, C. Y., Chen, X. H., Liu, Y. H., et al. (2023). Electrospun core-sheath PCL nanoﬁbers loaded with nHA and simvastatin and their potential bone regeneration applications. Front. Bioeng. Biotechnol. 11, 1205252. doi:10. 3389/fbioe.2023.1205252 Tan, C., Yuan, Z., Xu, F., and Xie, X. (2022). Electrospun cellulose acetate wound dressings loaded with Pramipexole for diabetic wound healing: an in vitro and in vivo study. Cellulose 29, 3407–3422. doi:10.1007/s10570-022-04466-0 Ranjbar-Mohammadi, M., Rabbani, S., Bahrami, S. H., Joghataei, M. T., and Moayer, F. (2016). Antibacterial performance and in vivo diabetic wound healing of curcumin loaded gum tragacanth/poly(ε-caprolactone) electrospun nanoﬁbers. Mat. Sci. Eng. c-mater. Biol. Appl. 69, 1183–1191. doi:10.1016/j.msec.2016.08.032 Teaima, M. H., Elasaly, M. K., Omar, S. A., El-Nabarawi, M. A., and Shoueir, K. R. (2022). Wound healing activities of polyurethane modiﬁed chitosan nanoﬁbers loaded with different concentrations of linezolid in an experimental model of diabetes. J. Drug Deliv. Sci. Technol. 67, 102982. doi:10.1016/j.jddst.2021.102982 Raspovic, K. M., Johnson, M. J., and Wukich, D. K. (2022). A stepwise approach to nonoperative and operative management of the diabetic foot ulceration. Phys. Med. Rehabil. Clin. N. Am. 33, 833–844. doi:10.1016/j.pmr.2022.06.004 Tomic, D., Shaw, J. E., and Magliano, D. J. (2022). The burden and risks of emerging complications of diabetes mellitus. Nat. Rev. Endocrinol. 18, 525–539. doi:10.1038/ s41574-022-00690-7 Frontiers in Bioengineering and Biotechnology 18 frontiersin.org Jiang et al. 10.3389/fbioe.2024.1354286 Tottoli, E. M., Dorati, R., Genta, I., Chiesa, E., Pisani, S., and Conti, B. (2020). Skin wound healing process and new emerging technologies for skin wound care and regeneration. Pharmaceutics 12, 735. doi:10.3390/pharmaceutics12080735 Yu, D.-G., and Huang, C. (2023). Electrospun biomolecule-based drug delivery systems. Biomolecules 13, 1152. doi:10.3390/biom13071152 Yu, D.-G., and Xu, L. (2023). Impact evaluations of articles in current drug delivery based on web of science. Curr. Drug Deliv. 21, 360–367. doi:10.2174/1567201820666230508115356 Udomluck, N., Koh, W.-G., Lim, D.-J., and Park, H. (2020). Recent developments in nanoﬁber fabrication and modiﬁcation for bone tissue engineering. Int. J. Mol. Sci. 21, 99. doi:10.3390/ijms21010099 Yu, D.-G., and Zhao, P. (2022). The key elements for biomolecules to biomaterials and to bioapplications. Biomolecules 12, 1234. doi:10.3390/biom12091234 Veves, A., Falanga, V., Armstrong, D. G., and Sabolinski, M. L. (2001). Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers. Diabetes Care 24, 290–295. doi:10.2337/diacare.24.2.290 Yu, D.-G., and Zhou, J. (2023). How can electrospinning further service well for pharmaceutical researches? J. Pharm. Sci. 112, 2719–2723. doi:10.1016/j.xphs.2023.08.017 Yu, D. G., and Zhou, J. (2024). Electrospun multi-chamber nanostructures for sustainable biobased chemical nanoﬁbers Next Mater. 2, 100119. doi:10.1016/j. nxmate.2024.100119 Vijayan, A., Nanditha, C. K., and Kumar, G. S. V. (2021). ECM-mimicking nanoﬁbrous scaffold enriched with dual growth factor carrying nanoparticles for diabetic wound healing. Nanoscale Adv. 3, 3085–3092. doi:10.1039/d0na00926a Zeng, C., Shao, Z., Li, J., Pan, H., and Xing, F. (2020). Commentary: metabolites released from apoptotic cells act as tissue messengers. Front. Immunol. 11, 1878. doi:10. 3389/ﬁmmu.2020.01878 Wang, H., Lu, Y., Yang, H., Yu, D.-G., and Lu, X. (2023). The inﬂuence of the ultrasonic treatment of working ﬂuids on electrospun amorphous solid dispersions. Front. Mol. Biosci. 10, 1184767. doi:10.3389/fmolb.2023.1184767 Zhang, H., Zhang, M., Wang, X., Zhang, M., Wang, X., Li, Y., et al. (2022). Electrospun multifunctional nanoﬁbrous mats loaded with bioactive anemoside B4 for accelerated wound healing in diabetic mice. Drug Deliv. 29, 174–185. doi:10.1080/10717544.2021. 2021319 Wang, J., Lin, J., Chen, L., Deng, L., and Cui, W. (2022). Endogenous electric-ﬁeldcoupled electrospun short ﬁber via collecting wound exudation. Adv. Mat. 34, 2108325. doi:10.1002/adma.202108325 Wang, M., Hou, J., Yu, D.-G., Li, S., Zhu, J., and Chen, Z. (2020). Electrospun tri-layer nanodepots for sustained release of acyclovir. J. Alloy. Compd. 846, 156471. doi:10.1016/ j.jallcom.2020.156471 Zhang, P., Jiang, Y., Liu, D., Liu, Y., Ke, Q., and Xu, H. (2020). A bioglass sustainedrelease scaffold with ECM-like structure for enhanced diabetic wound healing. Nanomedicine 15, 2241–2253. doi:10.2217/nnm-2020-0053 Wang, Y., Liu, L., Zhu, Y., Wang, L., Yu, D.-G., and Liu, L.-Y. (2023). Tri-layer core–shell ﬁbers from coaxial electrospinning for a modiﬁed release of metronidazole. Pharmaceutics 15, 2561. doi:10.3390/pharmaceutics15112561 Zhang, W., Liu, W., Long, L., He, S., Wang, Z., Liu, Y., et al. (2023). Responsive multifunctional hydrogels emulating the chronic wounds healing cascade for skin repair. J. Control. Release 354, 821–834. doi:10.1016/j.jconrel.2023.01.049 Wang, Y., Yu, D.-G., Liu, Y., and Liu, Y.-N. (2022). Progress of electrospun nanoﬁbrous carriers for modiﬁcations to drug release proﬁles. J. Funct. Biomater. 13, 289. doi:10.3390/jfb13040289 Zhang, X., Chi, C., Chen, J., Zhang, X., Gong, M., Wang, X., et al. (2021). Electrospun quad-axial nanoﬁbers for controlled and sustained drug delivery. Mat. Des. 206, 109732. doi:10.1016/j.matdes.2021.109732 Wu, J., Zhang, Z., Gu, J., Zhou, W., Liang, X., Zhou, G., et al. (2020). Mechanism of a long-term controlled drug release system based on simple blended electrospun ﬁbers. J. Control. Release 320, 337–346. doi:10.1016/j.jconrel.2020.01.020 Zhao, H., Lu, S., Chai, J., Zhang, Y., Ma, X., Chen, J., et al. (2017). Hydrogen sulﬁde improves diabetic wound healing in ob/ob mice via attenuating inﬂammation. J. Diabetes Complicat. 31, 1363–1369. doi:10.1016/j.jdiacomp.2017.06.011 Xu, L., He, H., Du, Y., Zhang, S., Yu, D.-G., and Liu, P. (2023). Electrosprayed core (cellulose acetate)-shell (polyvinylpyrrolidone) nanoparticles for smart acetaminophen delivery. Pharmaceutics 15, 2314. doi:10.3390/pharmaceutics15092314 Zhao, P., Chen, W., Feng, Z., Liu, Y., Liu, P., Xie, Y., et al. (2022). Electrospun nanoﬁbers for periodontal treatment: a recent progress. Int. J. Nanomed. 17, 4137–4162. doi:10.2147/IJN.S370340 Xu, X., Wang, X., Qin, C., Khan, A. U. R., Zhang, W., and Mo, X. (2021). Silk ﬁbroin/ poly-(L-lactide-co-caprolactone) nanoﬁber scaffolds loaded with Huangbai Liniment to accelerate diabetic wound healing. Colloid Surf. B-Biointerfaces 199, 111557. doi:10. 1016/j.colsurfb.2021.111557 Zhao, X., Bhagia, S., Gomez-Maldonado, D., Tang, X., Wasti, S., Lu, S., et al. (2023). Bioinspired design toward nanocellulose-based materials. Mater. Today 66, 409–430. doi:10.1016/j.mattod.2023.04.010 Zheng, X., Kang, S., Wang, K., Yang, Y., Yu, D.-G., Wan, F., et al. (2021). Combination of structure-performance and shape-performance relationships for better biphasic release in electrospun Janus ﬁbers. Int. J. Pharm. 596, 120203. doi:10.1016/j.ijpharm. 2021.120203 Yan, E., Jiang, J., Yang, X., Fan, L., Wang, Y., An, Q., et al. (2020). pH-sensitive coreshell electrospun nanoﬁbers based on polyvinyl alcohol/polycaprolactone as a potential drug delivery system for the chemotherapy against cervical cancer. J. Drug Deliv. Sci. Technol. 55, 101455. doi:10.1016/j.jddst.2019.101455 Zhou, J., Dai, Y., Fu, J., Yan, C., Yu, D.-G., and Yi, T. (2023a). Dual-Step controlled release of berberine hydrochloride from the trans-scale hybrids of nanoﬁbers and microparticles. Biomolecules 13, 1011. doi:10.3390/biom13061011 Yang, W., Tao, Y., Wu, Y., Zhao, X., Ye, W., Zhao, D., et al. (2019). Neutrophils promote the development of reparative macrophages mediated by ROS to orchestrate liver repair. Nat. Commun. 10, 1076. doi:10.1038/s41467-019-09046-8 Zhou, J., Wang, L., Gong, W., Wang, B., Yu, D.-G., and Zhu, Y. (2023b). Integrating Chinese herbs and western medicine for new wound dressings through handheld electrospinning. Biomedicines 11, 2146. doi:10.3390/biomedicines11082146 Yellin, J. I., Gaebler, J. A., Zhou, F. F., Niecko, T., Novins, O., Ockert, A., et al. (2022). Reduced hospitalizations and amputations in patients with diabetic foot ulcers treated with cyclical pressurized topical wound oxygen therapy: real-world outcomes. Adv. Wound Care 11, 657–665. doi:10.1089/wound.2021.0118 Zhou, J., Yi, T., Zhang, Z., Yu, D.-G., Liu, P., Wang, L., et al. (2023c). Electrospun Janus core (ethyl cellulose//polyethylene oxide) @ shell (hydroxypropyl methyl cellulose acetate succinate) hybrids for an enhanced colon-targeted prolonged drug absorbance. Adv. Compos Hybrid. Mater 6, 189. doi:10.1007/s42114-023-00766-6 Yin, H., Ding, G., Shi, X., Guo, W., Ni, Z., Fu, H., et al. (2016). A bioengineered drugEluting scaffold accelerated cutaneous wound healing in diabetic mice. Colloids Surfaces B Biointerfaces 145, 226–231. doi:10.1016/j.colsurfb.2016.04.056 Frontiers in Bioengineering and Biotechnology 19 frontiersin.org